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The interactions of viral matrix proteins with lipid 
membranes 
 
James Alexander Freeth 
 
 
Abstract 
 
This thesis describes the work undertaken to study the binding of lipid membranes by 
the viral matrix proteins hRSV-M and Influenza-A-M1. 
 
hRSV-M was recombinantly expressed and purified. It was the subjected to analysis 
by Langmuir-Blodgett trough experiments, Brewster angle microscopy, Confocal 
microscopy of giant unilamellar vesicles (GUVs), and binding studies with lipid 
nanodiscs. These studies showed hRSV-M having a preference for interacting with 
negatively charged lipids, namely phosphatidylserine, and for having different 
behaviours in Lo and Ld phases of membranes. 
 
During work on hRSV-M to improve its stability, it was discovered calcium stabilised 
the protein. This relationship was explored by ICPMS, differential scanning 
fluorimetry (DSF), circular dichroism (CD), mass spectrometry and microscale 
thermophoresis. This showed the hRSV-M is a calcium binding protein, containing 
two binding sites. 
 
Influenza-A-M1 was cloned into a plasmid vector and subsequently expressed and 
purified. The stability and structure of the protein was probed by DSF and CD 
measurements. The lipid interactions of this protein were then also explored by 
Langmuir-Blodgett trough isotherms and GUV binding under confocal microscopy. 
These showed that M1 is able to bind to phosphatidylserine containing membranes 
and causes vesicle budding from those membranes. 
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 1 
 
1 Introduction 
 
1.1 Viruses 
 
Viruses are infectious biological agents found in all ecosystems and believed to have 
existed since the earliest organisms. A Virus by itself is not considered to be alive, but 
must infect another organism in order to reproduce and propagate itself further .1  In 
general a virus consists of a genetic code in DNA or RNA surrounded by a 
nucleocapsid composed of structural proteins with other associated proteins involved 
in viral replication, fusion and budding. However, there is huge variation in different 
virus’ shape, size, genetics and host organism. Viruses have been found to infect all 
classes of organisms including eukaryotes, prokaryotes and archaea. However, 
individual viruses are restricted to being able to infect a small range of hosts. 
 
Broadly, viruses can be divided into 4 structural types. Helical viruses are those in 
which nucleocapsid proteins forms long oligomeric helical structures surrounding the 
genetic material inside the central hollow. This causes these viruses to form long 
filamentous structures. Icosahedral viruses have a symmetrical, almost spherical shell 
formed by identical nucleocapsid subunits. They consist of 20 triangular faces 
surrounding the central hollow containing the genetic material and other viral 
proteins. “Complex” viruses are those whose structures consist of different domains 
of varying constitution. A typical example of this is the structure of bacteriophages, 
which have an icosahedral head attached to a helical body segment with additional 
protein fibres stretching off it. The final type is enveloped viruses. In addition to a 
nucleocapsid, which may be of any of the above shapes, these viruses are surrounded 
by a membrane envelope derived from the host cell1. It is this class of virus that this 
project focuses on. 
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A) B) 
C) 
 
 
 
 
 
Figure 1 - Diagrams of typical A) Helical, B) Icosahedral and C) Bacteriophage viruses2 
(Reprinted with permission, Nature publishing group) 
 
Enveloped viruses consist of 3 main parts; the genetic material, the capsid and the 
envelope, along with other associated proteins. The capsid consists of individual 
repeating units called capsomers, which themselves may be made up of one or more 
proteins. These units are held together non-covalently to form a solid shell around the 
virus genome. The function of the capsid is to protect the inner genome and 
associated proteins from damage, and also to act as a scaffold for other proteins to 
attach to. For example, receptor proteins attach to the surface of the non-enveloped 
Polio virus capsid to target the virus to nerve cells. The capsid can also bind to the 
genome to aid the correct assembly of intact virions. This capsid – genome complex is 
called the nucleocapsid. The size of the capsid is directly related to how much 
material the virus has to carry inside it. Viruses have evolved to use the smallest 
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capsid size possible to fit the genome inside. In the case of enveloped viruses, the 
capsid may also directly interact with the membranous envelope, or with intermediate 
proteins which in turn adsorb to the envelope. 
 
The genomics of viruses are very diverse. The genome may consist of either DNA or 
RNA and in several different conformations. Viruses have been found with both 
double stranded and single stranded (+ or -) genomes, and genomes that must first 
undergo reverse transcription in order to be incorporated into the host genome. This 
variety has led to the Baltimore Classification system for viruses outlined in Table 1. 
 
Class Genome Example Virus 
I dsDNA Herpes Simplex Virus 
II (+)ssDNA Parvovirus B19 
III dsRNA Rotavirus 
IV (+)ssRNA Hepatitis C Virus 
V (-)ssRNA Influenzavirus A 
VI (+)ssRNA-RT HIV 
VII dsDNA-RT Hepatitis B 
Table 1 - The Baltimore Classification system for viruses.3 
 
The viruses being focused on in this project are of class IV and V, the single-stranded 
RNA viruses. Some example families of these are outlined in Table 2. 
 
Class Family Example Virus Capsid Shape Enveloped / 
Naked State 
IV Picornaviridae Poliovirus Icosahedral Naked 
IV Caliciviridae Hepatitis E Icosahedral Naked 
IV Togaviridae Rubella Virus Icosahedral Enveloped 
IV Flaviviridae Hepatitis C Virus Icosahedral Enveloped 
V Orthomyxoviridae Influenzavirus A Helical Enveloped 
V Paramyxoviridae hRSV Helical Enveloped 
V Rhabdoviridae Rabies Helical Enveloped 
V Filoviridae Ebola Virus Helical Enveloped 
Table 2 - Example Families of Class IV and V viruses and their structures. 
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Figure 2 – Simplified structure of a typical enveloped virus. (© The University of Waikato) 
 
The envelope surrounding an enveloped virus is a phospholipid bilayer that forms the 
outermost layer of the virion. It is derived from the host cell’s plasma membrane, 
formed as the virus buds, and so the lipid composition is similar to the host cell. The 
membrane can have a number of viral glycoproteins imbedded in it, which then 
appear on the outside of the virion. Due to the host derived nature, the envelope may 
also carry host proteins with it, but many of these are displaced by the viral ones. The 
envelope is attached to the central virus structure either directly, or through matrix 
proteins which bind to the membrane and nucleocapsid, holding them together. It is 
these types of membrane binding proteins that this project will focus on. The presence 
of a lipid envelope does make the virus more susceptible to damage, however the host 
derived material can help the virus to evade detection by the host organisms immune 
system, and the fusion that occurs between the envelope and cell membranes can help 
with the entry of the virus into cells. 
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1.2 Enveloped Virus Lifecycle 
 
 
Figure 3 - Host invasion and replication cycle of an influenza virus. Step 1: Binding. Step 2: 
Entry. Step 3: Complex formation and transcription. Step 4: Translation. Step 5: Secretion. Step 
6: Assembly. Step 7: Release. (© Boundless Learning, Inc under creative commons licence 
Sharealike 4.0) 
 
The lifecycle of a typical enveloped virus can be divided into five stages. The first is 
the attachment of the virus to the outside of the host cell. This is usually mediated by 
viral proteins on the outside of the envelope or nucleocapsid binding to receptors on 
the plasma membrane surface. This binding is followed by the internalisation of the 
James Freeth 2014 
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virus. This can occur by direct penetration of the virus through the cell membrane, 
however for enveloped viruses the most common method is through direct fusion of 
the envelope with the plasma membrane or through endocytosis and release at the 
endosome.4 Next the nucleocapsid is disassembled through degradation by viral or 
host proteases, or the capsid may spontaneously fall apart under a change in 
conditions such as changing pH. The virus is now free to replicate inside the host cell. 
The replication of a virus is different for all the different classes of viruses; however 
they all follow the same scheme. The DNA/RNA is replicated by polymerase 
enzymes and mRNA transcribed from them. This is then used by the host cell’s 
ribosomes to produce viral proteins. The newly produced proteins and genetic 
material can then be assembled to form the progeny virions. This assembly is an 
extremely diverse process and will be looked at in more details for the specific viruses 
to be studies in this project. Finally the virus is released from the cell either through 
eventual lysis of the whole cell or through budding of the virus from the membrane. It 
is at this point an enveloped virus normally acquires its envelope. 
 
1.3 Membranes and Lipid Domains 
 
Lipids are one of the most fundamental building blocks of a cell. They consist of a 
wide range of hydrophobic or amphiphilic molecules, linked either by their 
biosynthetic pathways or by function. There are so many different species classed as 
lipid that classification of them all is still not universally agreed.5 For biological 
systems, the most important lipids are considered to be the glycerol-phospholipids, 
along with certain sphingolipids and sterols. Phospholipids can be described as having 
a variable polar headgroup and two fatty acid tails. On their own, phospholipids will 
spontaneously form a variety of structures in water depending on their shapes. They 
arrange into structures that expose the polar headgroups to the water, while burying 
the hydrophobic fatty acid tails. The relative size differences between the headgroup 
and tails induce a curvature to any structures formed, the most important of which are 
detailed in figure 4. This will be important when looking at viral budding. 
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Figure 4 - The membrane curvature caused by different phospholipids, with examples. (© 
University of California, Davis under creative commons licence, from 
http://physwiki.ucdavis.edu) 
 
The first model to be developed for biological membranes was the Singer-Nicolson 
model.6 This model suggests that the membrane consists of a bilayer of freely 
diffusible phospholipids, studded with proteins. However this model only describes 
the gross morphology of membranes, since membranes consist of many different 
types of lipids showing different properties and a wide variety of proteins. 
 
  
 
 
Figure 5 - The Singer-Nicholson model of biological membranes. The green and red molecules 
are embedded or transmembrane proteins.7 (Reprinted with permission, Royal Society of 
Chemistry) 
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Figure 6 - Phases of DMPC bilayers8 (Reprinted with permission, Elsevier) 
 
Lipid bilayers exhibit lyotropic liquid crystalline properties. For example, figure 6 
shows the properties of DMPC. At low temperatures (<15°C) the Lβ’ phase is formed, 
followed by Lβ and Lc over time. Above 15°C Pβ’ is formed until above 24°C the Lα 
phase is formed. However, since biological membranes contain so many different 
lipid species, the phase behaviour of an actual membrane becomes much more 
complex and can vary greatly between membranes. 
 
When observing artificial membranes, it has been observed that with certain 
combinations of lipids two domains can coexist. These have been termed the liquid 
ordered (Lo) and liquid disordered (Ld) phases. The Lo domains have been observed to 
be areas enriched in cholesterol and sphingolipids, and lack conformational and 
rotational freedom.9 This is believed to be due to the intercalation of cholesterol 
between the fatty acid tails of the sphingolipids which prevents “kinks” forming in 
them and so greatly increases the temperature to form the Lα phase. The Ld phase is 
the surrounding disordered lipids which has full freedom on movement and 
conformation. 
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Figure 7 - A) AFM image of a DOPC/Cholesterol/SM membrane. B) Cartoon of Lo and Ld phases 
of a PC/SM/Chol lipid bilayer.10 (Reprinted with permission, American Chemical Society) 
 
 Interpreting these observations in vivo has been more difficult. For most 
earlier work, Lo domains have been identified with detergent resistant membranes 
(DRMs). These are membrane fractions found to remain intact after addition of a 
detergent. Since these fractions contain large amounts of sphingomyelin and 
cholesterol, and form Lo-like structures, it was thought that these may be the Lo 
domains from the cell membrane.11, 12 However while this has been useful 
experimentally it is contested by some that since using detergents alters the lipid 
profile of the extracted membrane and that different preparation of DRMs produces 
different membrane compositions, they cannot be directly identified as existing in this 
state in vivo.13 
 
The result has been the “raft” hypothesis of biological membranes, so called because 
areas of Lo domains are thought to float in the “sea” of lipids in the same way as 
proteins do in the Singer-Nicolson model. These rafts are distinct transient 
microdomains, of a scale that makes them difficult to study directly, often showing 
different behaviour from model Lo/Ld systems.
14 These rafts are thought to exist on 
both envelopes of the membrane, although whether they must exist together is still 
unknown.15  Most evidence for raft formation has come from studies showing that 
certain proteins and lipids cluster together, however this has only been shown for very 
small clusters, suggesting that rafts are of a much smaller size than artificial Lo 
domains or DRMs.16 However, as new methods are developed we are getting closer to 
being able to see rafts and raft behaviour at the nano scale on the cell surface.17 
 
Rafts domains have been implicated in a large number of processes, ranging from 
signal transduction12 to membrane sorting and organising.18 However, they have also 
been implicated in the assembly of enveloped viruses.19 The theory of this is that 
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when an enveloped virus buds it needs to take viral glycoproteins with it in the 
envelope membrane, this process is much more efficient when the glycoproteins are 
clustered together and the uncoated progeny virus is directed towards them. This 
clustering is thought to take place in lipid rafts, and the matrix protein which 
surrounds the nucleocapsid interacts with these lipid rafts. This is supported by 
evidence in several viruses that viral glycoproteins co-localise with other raft markers, 
such as GM-1,20, 21 that viral envelopes are enriched in cholesterol and 
sphingolipids,22 and efficient viral assembly requires functional raft domains.23 
  
1.4 Respiratory Syncytial Virus 
 
1.4.1 The Virus and Disease 
 
Respiratory Syncytial Virus is a member of the family Paramyxoviridae of the 
Mononegavirales. It is a class V, enveloped virus with a single stranded negative 
sense RNA genome. The virus is endemic and is the “single most important cause of 
severe LRIs in infants and young children”24. There are an estimated 64 million cases 
worldwide every year and 160,000 deaths resulting from respiratory problems. The 
virus infects the upper respiratory tract before progressing to the lower tract. 
Symptoms begin with wheezing and shortness of breath caused by the immune system 
damaging lung epithelial cells in an attempt to remove the infection. This can lead to 
complications of pneumonia, where fluid from damaged cells leaks into the 
bronchioles, causing a decrease in oxygen uptake and a risk of secondary infections.25 
The disease has been recognised as an increasing problem in the elderly, and the 
potential problems this will lead to as populations age.26 Despite this, there is 
currently no vaccine or effective treatment beyond broad antiviral drugs. A humanised 
monoclonal antibody to the fusion (F) protein is available under the name 
palivizumab however this only provides short term immunity and so must be updated 
with several doses. The high cost of this treatment makes it unattractive to all but the 
richest countries. 
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hRSV consists of 11 proteins, encoded in 10 cistrons of a single stranded RNA 
genome. 
 
Figure 8 – Genome map of hRSV (©ViPR http://www.viprbrc.org) 
 
The Nucleoprotein (N) encapsulates the RNA genome as a helical complex which 
protects the genome and serves as a scaffold for the proteins involved in replication to 
attach. 27, 28 The viral ribonucleoproteins complex (vRNP) consists of this 
nucleoprotein complex and attached Phosphoprotein (P), Large Polymerase (L), and 
two Matrix protein 2 isoforms (M2-1 and M2-2). The Phophoprotein acts to stabilise 
the large polymerase and to aid it correctly binding the N-RNA complex.29 The L 
protein itself is responsible for all RNA activity, such are replication, methylation and 
polyadenylation.30 M2-1 aids in transcription and processing of RNA through binding 
the other vRNP components, while M2-2 is less well known but may be involved in 
the regulation of RNA transcription and regulation. A pair of proteins expressed are 
called non-structural proteins 1 and 2 (NS1 And NS2). These proteins are very poorly 
characterised, however have been shown to inhibit apoptosis and limit the host cell’s 
immune response through the interferon pathway.31, 32 
 
The viral envelope consists of lipids derived from the host cell, and is studded with 
three transmembrane proteins. The Fusion Glycoprotein (F) is involved in the fusion 
of the viral envelope with the target cell upon infection and for cell to cell fusion and 
syncitium formation.33 The Attachment Glycoprotein (G) mediates the attachment of 
the virion to the target cell during infection.34 The SH (Small hydrophobic) protein is 
mostly unknown in function, but may be involved in inhibiting apoptosis.35 Between 
the viral envelope and the vRNP core sits the Matrix protein (M). This is the main 
structural protein of the virus and it binds the two components together. As the focus 
of this project, it will be discussed further below. 
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Figure 9 - Schematic of the structure of hRSV (©Swiss Institute of Bioinformatics, with 
permission) 
 
While the virus replicates in the cytoplasm, assembly and budding of the virus occurs 
at the cell membrane.36 In particular it is directed towards the apical membrane of 
lung epithelial cells, presumably to aid the further spread of the infection in the 
host.37, 38 The virion can be spherical or filamentous, with filamentous being the 
predominant form.37 
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1.4.2 The Matrix Protein 
 
Figure 10 - 3D crystal structure of hRSV-M (PDB = 2VQP). N-terminus is in blue, C-terminus in 
Red.39 
 
 
Figure 11 - Electrostatic surface potential (calculated with APBS) for hRSV-M, presented in a 
colour range from red to blue (−5 to +5 kT/e); uncharged residues are uncoloured. 
 
 
The matrix protein (M) is an essential part of the virion, being implicated in virus 
assembly, budding, structural stability and some regulatory functions during the 
viruses lifecycle. M has two domains, N- and C- terminal, joined by a flexible linker 
region to give the full 256 amino acid protein. It has a large (600 Å2) positively 
charged patch on its surface, across both domains, and also contains a large number of 
exposed tyrosines on the C-terminal.39 Both of these may contribute to the M 
protein’s ability to bind membranes,40 with it hypothesised that the C terminal is most 
responsible for membrane binding, and the N terminal for protein-protein 
interactions.41 By interacting with the host cell plasma membranes and the 
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nucleocapsid, the matrix protein holds the two together and facilitates the final 
assembly and budding of the virus.42 M binds the envelope via interactions with F, G 
and with the membrane itself,39, 43 and binds to the nucleocapsid via M2-1.44 It has 
also been found that M is one of the few proteins needed to make virion-like particles 
(VLPs), while in other related viruses matrix proteins can form VLPs by 
themselves.45, 46 This suggests that M may be very important in assembly of the virus 
into the correct shape. 
 
Data collected by our group previously suggests that M is able to adsorb to the Lo 
phase surface of a DOPC / Sphingomyelin / Cholesterol monolayer.47 In-vivo studies 
have also shown the M is co-purified with detergent resistant membranes, although 
whether this is dependent on viral glycoprotein presence is disputed.48, 49 
 
M protein has also been shown to have other possible functions. Early on in viral 
infection the protein localises to the nucleus and may limit host RNA translation. 21 
Late in the viruses life cycle M can be found in inclusion bodies, along with vRNPs, 
so it is suggested that M plays a role in the halting of transcription through an 
interaction with N.21, 50  
 
1.5 Influenza A 
 
1.5.1 The virus and disease 
Influenza A is a virus of the family Orthomyxoviridae. It is a class V, enveloped virus 
with a single stranded negative sense RNA genome. The Influenza A virus is an 
extremely common infection, which infects an estimated  5-10% of the global adult 
population and 20-30% of children annually.24 The disease is endemic in all 
populations, typically being most active during the winter months when closer living 
conditions aid its spread. Although the disease is usually mild, with symptoms 
including fever, sore throat and headaches, it is still a high risk disease among the 
very young, old and the immune compromised. There are an approximately 36,000 
deaths each year attributed to influenza in the US alone each year, and a large 
economic cost associated with treatment and lost work hours. While the influenza 
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viruses are a family of their own, they share many similarities with other RNA 
viruses.51 Along with their wide variety of hosts, this makes them a prime candidate 
for research. 
 
 
Figure 12 – Top: Structure of the Influenza virus A (© Dr Vincent Racaniello, 
http://www.virology.ws,  under Creative Commons Attribution 3.0 License). Bottom the 
segmented genome of Influenza A. (©Swiss Institute of Bioinformatics, with permission) 
 
 The segmented genome of Influenza A encodes eleven different proteins. 
These make up the viral nucleocapsid and surrounding viral envelope. The 
nucleocapsid consists of the RNA polymerase enzymes PA, PB1, PB1-F2 and PB2. 
These are involved in the replication of the virus genome in the host cell.52 The viral 
RNA is then packaged up with the NP (Nucleoprotein) protein in the nucleocapsid. 
These are supplemented in the nucleocapsid by the NS1 protein, which prevents the 
host cell’s anti-viral response53, and by the Nuclear Export protein (NEP), which 
exports the nucleocapsid complex from the nucleus once it is assembled.54 The 
envelope of the virus consists of the phospholipid bilayer derived from the host cell 
membrane, which is then studded with viral proteins. The transmembrane proteins 
involved are arguably the most important ones in the virus attacking a cell and in its 
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recognition by the immune system. The ion channel M2 is involved in the 
equilibration of pH between the virus and host cell during viral maturation, and later 
in the acidification of the virus upon entry into a cell to release the nucleocapsid from 
the envelope.55 The neuramidase (NA) and hemagglutinin (HA) proteins have large 
domains facing outward from the virus. These proteins assemble in lipid raft domains 
during viral maturation,56 and on the luminal side interact with the matrix protein to 
attach the holonucleocapsid to the membrane.57 The NA protein is involved in the 
maturation of the virus, by cleaving sialic acid residues from the surface of the 
assembled virus to aid its release from lung cells, while the HA protein binds to target 
cells during viral infection, leading to the entry of the virus. They are also currently 
the most important antigenic proteins of Influenza A, with Influenza infections being 
characterised by the subtypes of these proteins (N1-9, H1-17) and are how the body 
recognises the infection.58 Due to this they form major targets for drug discovery. The 
final Influenza A protein is the matrix protein. 
 The Influenza A virion may form in two different shapes. Some strains, such 
as A/Puerto Rico/8/1934 H1N1, bud as spherical virions, while others, such as 
A/Udorn/1972 H3N2, bud into a filamentous form.59 While this difference has been 
hypothesised to be due to difference in the structural proteins, it is also observed that 
most virions in a clinical setting are observed to be filamentous, and that differences 
may be less pronounced.60, 61 
 
1.5.2 The Matrix Protein (M1) 
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Figure 13 - 3D Structure of Influenza A Matrix Protein N-terminus62 
 
The Matrix protein of Influenza A (M1) is a 28 KDa, 252 amino acid protein, and is 
the main structural protein in the virion. The protein has many similarities with other 
matrix proteins, and is believed to share a common ancestor with HIV MA and other 
negative sense RNA virus matrix proteins.51 The protein is commonly divided into 2 
domains, the N domain and C domain which are joined by a linking region, 
sometimes referred to as the M domain. The crystal structure for a N fragment of this 
protein has been solved (residues 2-158) which showed that it is mostly alpha helical 
in secondary structure.63 The C terminal domain is believed to be weakly structured, 
and studies looking at which amino acid residues are solvent exposed show the linker 
region and most of the C domain to be exposed.64 M1 also contains a zinc finer 
domain, and 15% of the M1 in purified viruses has zinc bound at this location.65 
While the direct action of this site is unknown, it has been mapped as important to 
vRNA binding.66, 67 
 
M1 has been shown to have multiple functions in the life cycle of the virus. 
Interactions with components of the classical complement pathway have been shown, 
suggesting M1 has a role in protecting the virus from the host cell immune response.68 
M1 has also been found to contain a nuclear localisation sequence which allows it to 
be imported into the nucleus. There its first role in the assembly of the virus is the 
inhibition of transcription of viral RNA (vRNA). M1 is able to directly bind vRNA 
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and thus halt transcription, but it is also able to bind the viral ribonucelocapsid 
(vRNP) and halt transcription in favour of NP-RNA formation and formation of 
further vRNP.69-71 Following this, M1 is involved in the export of vRNP from the 
nucleus. It achieves through binding of the vRNP and NEP to create a daisy-chain 
structure of Crm1/RanGTP-NEP-M1-vRNP, which is then targeted to the nucleopore 
complex for export.54, 72-74 Once exported, M1 prevents the import of vRNPs back into 
the nucleus.75 M1 will also interact with the actin cytoskeleton, possibly to aid 
transport away from the nucleus and towards the membrane.76, 77 
 
As the major structural protein, M1 is heavily involved in assembly and budding of 
the virion. M1 has been shown to assemble at the plasma membrane by two distinct 
processes. The transmembrane proteins HA and NA interact with M1 through their 
cytoplasmic tails and have been shown to stimulate its recruitment to the membrane 
during the late stages of infection, resulting in co-localisation in vivo and co-
purification with detergent resistant membranes.78, 79 M1 also interacts with the 
cytoplasmic tail of M2, which has been shown to be required for virus formation.80, 81 
However M1 also binds to membranes without the presence of these proteins.79, 82 In 
vivo M1 was found to associate stably with membranes, with both high salt conditions 
high pH and the mutation of surface hydrophobic residues unable to remove the 
association with membranes.82 Electron microscopy has shown M1 bound to the 
periphery of the lipid envelope in mature viruses.83 Studies on the N- and C- terminus 
of the protein have shown that only the N-terminus is in involved in membrane 
binding, and that it binds to negatively charged membranes.70 The oligomerisation of 
M1 on the face of the plasma membrane also works to exclude host cell membrane 
proteins from the site and recruit other viral components for maturation.52 
 
M1 bound to membranes is the major cause of viral budding for Influenza A. When 
M1 is limited viral particles are unable to bud from the membrane surface.84 When 
M1 is expressed in cells it is able to bud from the membrane to form virus-like 
particles (VLPs), either with or without the presence of other viral particles, although 
the efficiency is reduced.85, 86 Furthermore, M1 from different strains of Influenza A 
has the ability to dictate the form the virion takes during budding, with either 
filamentous or spherical forms of the virus depending wholly on the presence of M1, 
possibly through its interaction with the ribonucleoproteins.60, 87, 88 
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1.6 Other examples of viral matrix / core proteins 
 
1.6.1 Ebola VP40 
 
Figure 14 - X-ray crystal structure of Ebola VP40 (residues 44-326). PDB ID = 1ES6 89 
 
Ebola VP40 is a matrix protein which has been shown to be involved in viral budding 
and morphogenesis. It consists of an N- and C- terminal domains, of which the C-
terminal has been identified as required for membrane binding. Experiments have 
shown a preference for VP40 binding negatively charged lipid membranes, however 
only when in the monomeric state.90 VP40 exists in different oligomeric states at 
different parts of its life cycle. The presence of octomers of VP40 has been shown to 
be required for viral replication and the regulation of transcription.91, 92 It is still 
unclear how the virus coordinates the formation of these multimers throughout the 
lifecycle.93  
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1.6.2 Newcastle Disease Virus Matrix 
 
Figure 15 - X-ray crystal structure of NDV M. PDB ID = 4G1G 
 
Newcastle disease virus (NDV) matrix protein (M) has been shown to have membrane 
binding, nucleocapsid binding and regulatory function during infection. Binding to 
membranes has been observed to occur with neutral, negative charged and positively 
charged lipids, suggesting a strong hydrophobic interaction is driving adsorption.94 In 
vivo NDV-M protein alone is able to form VLPs, although this requires the integrity 
of lipid rafts in the cell to be possible.95, 96 Interestingly, when NDV-M is able to 
spontaneously bud from a membrane in vitro to form coated liposomes, indicating 
that it can induce curvature on a membrane.97 NDV-M also has a nuclear localisation 
sequence and interacts with the RNP, possibly to regulate transcription.98, 99 
 
1.6.3 Hepatitis C Virus Core protein 
 
HCV core protein is synthesised as a 22 kDa polypeptide that is inactive.100 This 
polypeptide has been shown to need processing by the host enzymes signal peptidase 
(SP) and signal peptide peptidase (SPP) before mature virus can form.101-103 This 
appears to allow the protein to fold correctly. Unlike matrix proteins, core protein 
itself forms the capsid, and is able to bind to RNA directly.104 The lipid binding of the 
protein has been shown to be slightly different from matrix proteins as well. Core 
protein is mainly found localised to lipid droplets in hepatocyte cells, a property not 
seen in other Flaviviridae.105, 106 The presence of core protein has a dramatic change 
on these lipid droplets, leading to an increase in amount, size and a change in cellular 
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localisation.107-109 The loss of lipid droplets actually stops the production of the virus, 
suggesting that assembly occurs at this point.110, 111 Detailed examination of these 
lipid droplets shows that virus budding and assembly actually occurs at ER 
membranes closely associated with the lipid droplet, however why lipid droplets must 
then be present is unknown.112 The domains found to be essential for binding lipid 
droplets are believed to be unique among viruses, however may show some similarity 
with plant oleosin proteins.113, 114 While the domains that may be involved in lipid 
binding have been identified, domains 1 and 2 particularly, there has been little work 
on the specifics of this interaction.115, 116 Furthermore, recently it has been shown that 
core protein is palmitoylated, and is required for core to associate with the ER 
surrounding lipid droplets.117 Expressed alone, the core protein has been shown to 
form VLPs, suggesting it is the major contributor to viral assembly and budding.118 
Other roles of the core protein have also been identified, such as up regulating genes 
involved in lipid accumulation and in downregulation of DNA repair.118 
 
1.7 The scope of this research 
 
The aim of this project is to study the structure and properties of hRSV-M and Inf-
M1. With respect to hRSV-M, much of this work is a continuation of that done by 
Helen McPhee in previous years and published by our group, which although it has 
shed much light on the matrix protein has also left many more questions to be 
answered.47 The interactions of M with artificial membranes have been probed, but 
there are still many combinations of lipids that have not been examined yet. Direct 
imaging of hRSV-M localising to these membrane systems has also not been achieved 
and the partitioning of M into different lipid domains has not yet been confirmed. 
There are also questions about possible changes in hRSV-M conformation upon 
membrane binding, and why mass spectrometry experiments have previously found 
an aberrant mass at +80 Da. 
 
We also wish to carry this work on to the related matrix protein (M1) from Influenza 
A, to answer many of the same questions. The behaviour of this protein with 
membranes has been very poorly studied; with little know beyond an association with 
negatively charged lipids. 
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This project will utilise many different techniques in order to probe protein 
interactions with membranes, including thin film (Langmuir-Blodgett) techniques, 
Brewster angle microscopy and confocal microscopy. The structures of the proteins 
will also be investigated by circular-dichroism measurements, differential scanning 
fluorimetry, thermophoresis and dynamic light scattering. 
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2 Results - hRSV Matrix protein 
 
2.1 Purification and Stability issues 
 
 
Table 3 - The amino acid sequence for hRSV-M, including histidine tag. residues in brackets are 
retained after tag removal 
 
hRSV Matrix protein was expressed as a recombinant protein from the plasmid vector 
pET16b-hRSV-M. This vector is designed to express the protein with an attached 
Hisidine tag and Factor Xa cleavage site at the N-terminus for purification. 
Expression and purification were carried out following previously established 
protocols47. In brief, the vector was transformed into the E.Coli strain 
BL21(DE3)pLysS and expressed after induction by the addition of IPTG to a final 
concentration of 1mM. The cells were harvested and the protein purified by a one step 
Immobilised Metal Affinity Chromatography purification. Fractions from the 
purification were analysed by SDS-PAGE and clean fractions were pooled (Figure 
16) and the Histidine tag removed by Factor Xa cleavage. The protein finally dialysed 
into a PBS buffer.  
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Figure 16 - Purification of hRSV-M. Lane 1- Protein ladder, lane 2- unpurified hRSV-M, lane 3- 
flow through from IMAC, lanes 4-7 Elutions from Ni-IMAC at 50-500 mM Imidazole, Lane 8- 
hRSV-M with 6xHis tag removed 
 
 
While this protocol had been used in previous work to produce the protein, during this 
work the protein often presented stability problems. Following purification the protein 
would precipitate out of solution overnight, leaving very little material behind for 
performing experiments. This precipitation was observed occurring independent of 
storage conditions, although increasing temperatures made this worse as expected for 
many proteins. 
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Figure 17 - Graph showing change in protein concentration of a purified sample of hRSV-M 
from day of purification (Day 0) to day 4 
 
 
This change in behaviour of the protein was attributed to a change in the laboratory in 
which it was purified, and hence a change in some condition. When initial attempt to 
improve the stability failed, an approach was taken to identify and stabilising or 
destabilising elements involved in the purification. 
 
2.2 Differential Scanning Fluorimetry 
 
One method for exploring protein stability is to look for changes in the denaturation 
temperature of the protein, Tm. By looking at changes in the Tm of the protein upon 
exposure to different chemicals or ligands, we an determine those that have a positive 
or negative influence on stability and possibly also identify new specific ligands for 
the protein119. The method adopted for studying hRSV-M was differential scanning 
fluorimetry. Briefly, the protein is mixed with the ligand or chemical to be tested and 
the fluorescent dye Sypro Orange. The sample is then loaded into a qPCR machine 
and change in fluorescence is monitored as the temperature is slowly increased. 
 
Sypro Orange fluoresces at 570nm on excitation however it is strongly quenched by 
surrounding water. It also shows strong nonspecific binding to hydrophobic 
surfaces120. This makes it an ideal indicator for exposed hydrophobic surfaces on a 
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protein. One characteristic of the majority of soluble proteins is that they present 
hydrophilic surfaces on their exterior and hydrophobic surfaces are buried on the 
interior, hence increasing the entropy of the system. This is one of the major driving 
forces behind protein folding.121 However when a protein is denatured, by heating or 
chemicals means such as urea, these hydrophobic surfaces and amino acids become 
exposed as the protein’s tertiary structure unfolds. Thus using the fluorescence of 
Sypro Orange as an indicator, we can follow the denaturation of a protein as it 
proceeds from folded to an unfolded state. 
 
hRSV-M was first tested with the protein in its initial purification buffer, PBS, against 
a screen of 96 different chemicals from Hampton Research (Solubility & Stability 
Screen, HR2-072). This screen contains a range of conditions, focusing on different 
pH and buffer conditions (pH 3.5-9.6) and numerous small additives that have 
previously been identified as stabilising some proteins in experiments. While all these 
conditions were tested, only those showing significance are shown below. All Tm’s 
were calculated by fitting the appropriate section of each data to a sigmoidal 
Boltzmann distribution and the point of inflection calculated. 
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Figure 18 - DSF data for hRSV-M in PBS buffer with addition of chemicals 
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Additive  Tm (°C) ∆Tm (°C) 
None (PBS buffer) 47.0 - 
200mM Phosphate buffer pH 7.4 47.5 0.5 
10mM CaCl2 and MgCl2 58.8 11.8 
10mM EDTA 43.0 -4.0 
50mM MgSO4 48.0 1.0 
Table 4 - Tm values for hRSV-M with additives used in DSF experiments in phosphate based 
buffer 
 
As can be seen in figure 18, the additives that showed the greatest change were all 
involved in metal binding. The addition of EDTA was shown to decrease the Tm of 
hRSV-M by 4°C, along with many denaturing chemicals such as urea (data not 
shown). EDTA is a strong chelator of many metals, and so it is reasonable to assume 
this reduction in stability is due to metals being removed from coordination with the 
protein. The strongest additive which showed an increase in protein stability was a 
mixture of calcium ions and magnesium ions, which together gave an increase in Tm 
of 11.8°C. Comparing this with the comparatively small change when only 
magnesium ions were added in higher concentration, this suggests that calcium is 
having a stabilising role.  
 
However, this experiment was performed with the protein in a PBS buffer, as has 
been used previously for experiments on this protein in our group. The sample with 
200mM phosphate ions added shows that while additional phosphate itself has no 
effect directly on the protein, it is well known that both magnesium and calcium form 
insoluble precipitates with phosphate ions. It is therefore possible that phosphate ions 
are having a negative effect on stability through the removal of these ions from 
solution. To test this, the experiment was repeated except the hRSV-M being purified 
in a Tris based buffer (50mM Tris, 200mM NaCl), and tested separately against the 
adding of phosphate ions, calcium ions and magnesium ions. 
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Figure 19 - DSF data for hRSV-M in Tris-based buffer 
 
It should be noted that the discontinuity in the data for some of the additives was due 
to a mechanical error, and data points below 47°c were not used in their fittings 
 
Additive  Tm (°C) ∆Tm (°C) 
None (PBS buffer) 57.2 - 
25mM Sodium Phosphate  50.4 -6.8 
500µM CaCl2 62.5 5.3 
500µM MgCl2 57.6 0.4 
500µM CaCl2 and 500µM MgCl2 62.6 5.4 
Table 5 - Tm values for hRSV-M with additives used in DSF experiments in Tris-Hcl based buffer 
 
As can be seen in figure 19, with phosphate removed from the buffering conditions, 
the stability of the protein is immediately improved, increasing the Tm by 6.8°C. 
Furthermore, by studying the addition of calcium and magnesium ions separately it 
can be seen that only calcium ions have an effect on the stability of hRSV-M. The 
addition of magnesium ions has no further effect than the addition of calcium ions 
alone. This gives the possibility that when added to hRSV-M in a PBS buffer, the 
magnesium ions were acting to remove some of the phosphate from the solution by 
precipitation, and so was having a synergistic effect with the calcium ions. While the 
calcium ions are now shown to have a smaller effect on the Tm of 5.4°C, the effect is 
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still significant and so onwards from this experiment hRSV-M was always purified in 
buffers without phosphate and containing 10mM CaCl2, before dialysis into 
appropriate buffers for experiments.  
 
However, this result was entirely unexpected and so further experiments were planned 
to see what the nature of this interaction with calcium is.  
 
2.3 Inductively coupled plasma mass spectrometry 
 
The technique of inductively coupled plasma mass spectrometry (ICPMS) is used to 
detect the presence of metal ions in a solution. For proteins, this allows for the protein 
directly examined to see what metals ions are found associated with it. This technique 
is sensitive enough to accurately determine the number of metal atoms in the sample 
and hence work out the stoichiometry of the metal binding to the protein. 
 
For this experiment, hRSV-M was first incubated with 100mM CaCl2 and 100mM 
MgCl2, and then buffered exchanged into a metal free buffer (10mM MOPS PH 7.4) 
using a PD-10 desalting column (GE Healthcare). The protein concentration was 
measured in each 0.5ml fraction from the column, and then 300 µl of each sample 
added to 2.4 ml 100% Nitric Acid and 300µl water. The samples were then analysed 
by ICPMS along with references solutions containing calcium and magnesium ions of 
known concentration. The results shown below are an average of 3 separate readings. 
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Figure 20- ICPMS data for calcium ions detected in fractions from PD-10 column after applying 
hRSV-M, and protein concentration for those fractions 
 
 
Fraction 
No. 
Protein 
concentration 
mg/ml 
Protein 
Concentration 
µM 
Calcium 
concentration 
(ppm) 
Calcium 
concentration 
µM 
Occupancy 
of calcium : 
hRSV-M 
5 0.097 3.39 0.161 2.958 0.87 
6 0.192 6.65 0.385 7.558 1.14 
      
   Average occupancy 1.00 
Table 6 - Results from ICPMS experiments on hRSV-M 
 
The data shows that the stoichiometry of hRSV-M binding to calcium is 1:1 under 
these conditions, and that magnesium does not bind in any measurable amount. This 
result does not match x-ray crystallography data which showed no metals bound to 
hRSV-M.39 However, this may indicate that binding is quite weak. In this experiment 
the protein was incubated with a high concentration of calcium just prior to the 
measurements, while the previous x-ray crystallography experiments were carried out 
with protein that had been purified in a way to that would have removed any calcium 
present.  
 
2.4 Microscale Thermophoresis 
 
Experiments in this section were carried out with the kind expertise of Dr Stefan Duhr 
from NanoTemper Technologies, and with the temporary loan of their equipment. 
James Freeth 2014 
 31 
 
In order to examine the nature of calcium ions binding to hRSV-M, microscale 
thermophoresis was utilised. Thermophoresis is the effect seen when a temperature 
gradient is applied to particles in a gas or liquid mixture. Since the properties of the 
particle change how it behaves in response to the temperature gradient, whether they 
move towards the heated area or away from it, this method can be used to probe the 
association or dissociation of particles. 122 
 
The motility of any biomolecule in a temperature gradient in aqueous medium is 
governed by its hydration shell. In the case of proteins many factors can change the 
hydration shell, including protein structure, amino acid modification and small 
molecule binding. Since changes in motility are measured across a sampling of 
molecules, by measuring the changes over sequential conditions the effect of the 
changes can be quantified. In the case of molecules binding to the protein, this means 
that the KD can be calculated from a serial dilution of the molecule applied to the 
protein.123, 124 
 
To perform Microscale Thermophoresis, the protein is first labelled with a fluorescent 
marker, to allow its movement to be tracked. hRSV-M was labelled with the dye NT-
647, a red fluorescent dye that modifies primary amines via a NHS-ester group. The 
sample is then mixed with a serial dilution of the additive molecule, in this case a 
range of calcium chloride solutions from 10 µM to 0.1 nM, and taken up into 4 µl 
capillary tubes to be loaded into the microscale thermophoresis apparatus 
(NanoTemper Monolith NT.115 Series). The process of taking a measurement for 
thermophoresis is detailed in figure 21. In brief, an infrared laser is directed at the 
capillary tube and after base-line fluorescence measurement is taken, the laser is 
switched on. This creates a localised heat spot generating the temperature gradient. 
The sample undergoes an initial temperature jump during which molecules rapidly 
move while the gradient is set up over the small area, resulting in a large drop in the 
fluorescence. This is then followed by the thermophoresis stage, which occurs over a 
10-30 second time period and is the state in which the molecules are diffusing along 
the temperature gradient. Once the molecules have reached a steady state, the 
fluorescence difference between this state and the state before the infrared laser was 
switched on can be used to calculate the change in molecule concentration in the 
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heated spot. By taking these readings over a range of binding partner concentrations, 
the KD can be determined by fitting to the equations detailed below. 
 
 
Figure 21 - A typical microscale thermophoresis measurement, showing the different stages and 
molecular movements. ©NanoTemper Technologies GmbH 
 
 
Thermophoresis can be described by the difference between the concentration of 
molecules in the heated area and the concentration in the cold area, and how this 
change is brought about by a change in the diffusion coefficient as described by the 
following equation.124 
)exp( TS
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Equation 1 
 
Where Chot is the concentration in the hot area, Ccold is the concentration in the cold 
area, ∆T is the change in temperature between the two areas and ST is the Soret 
coefficient, which is defined in equation 2 as the ratio of the diffusion coefficient (D) 
and the thermal diffusion coefficient (DT). 
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Equation 2 
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Since the temperature and concentration changes involved in microscale 
thermophoresis experiments are small, equation 1 can be approximated to equation 3. 
TS
c
c
T
cold
hot
∆−=1
 
Equation 3 
 
The thermophoresis experiments are used to yield a normalised fluorescence value 
Fnorm, as the ratio of the fluorescence change between the cold and hot states, and so 
can be fitted into equation 3 to give equation 4, where δF/δT is the change in 
fluorescence of the fluorophore with temperature. 
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Equation 4 
 
Since Fnorm is in linear relationship with the fraction of binding partner bound to the 
protein, the fraction bound (FB) is described by equation 5. 
 
boundnormunboundnormnorm FFBFFBF ⋅⋅ +−= )()1(
 
Equation 5 
  
If it is assumed that the law of mass binding action applies to this situation, with 
simple binding partners A and B, then the KD can be expressed as equation 6. 
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Equation 6 
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By taking the fraction bound FB from equation 5 as the fraction of B in equation 6; 
and solving the combined equation for B, equation 7 is derived. 
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Equation 7 
 
Using the relationships in equations 5 and equation 7, it is hence possible to calculate 
the KD for a small molecule binding a protein by measuring the change in 
fluorescence during thermophoresis. By plotting a graph of Fnorm against binding 
partner concentration, the resulting data points can be fit to equation 7.123 This process 
applied to the following data. 
 
Samples of hRSV-M were tested with varying concentrations of calcium chloride and 
produced the following results. 
 
 
Figure 22 - Microscale Thermophoresis results for “higher” affinity binding. Y-axis shows 
fluorescence (A.U), X-axis shows concentration of Calcium Chloride (µM) 
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Figure 23 - Microscale Thermophoresis results for “lower” affinity binding. Y-axis shows 
fluorescence (A.U), X-axis shows concentration of Calcium Chloride (µM) 
 
The microscale thermophoresis experiment showed two separate binding events for 
hRSV-M and calcium. The first was a “higher” affinity binding event, which resulted 
in a reduction in motility of HRSV-M with the addition of calcium, giving a 
calculated KD of 1.95x10
-6 M. The second was a significantly weaker binding event, 
giving an increased motility of HRSV-M down the temperature gradient formed, with 
a calculated KD of 1mM. A typical concentration of free calcium within lung cells is 
50-250 nM, while that in the extracellular fluid is much greater, approximately 1-2.5 
mM.125 While these values suggest that while inside a cell hRSV-M would not have 
calcium bound, the levels of calcium in a cell can vary greatly by compartment, with 
endoplasmic reticulum levels reaching several hundred µM. Furthermore, the 
infection of cells by a virus has been shown to increase the levels of calcium inside a 
cell further.126, 127 In hRSV the SH protein has been found to act as a cation-selective 
channel, and would likely lead to a large increase in internal free calcium as it leaks in 
from the extracellular fluid.128 This suggests that the two calcium binding sites 
correspond to different functions and will have different occupancies depending on 
the stage in the virus’s lifecycle. The high affinity binding site would likely be filled 
first while inside the cell when the intracellular calcium concentration is raised by the 
virus. This may be a signal for virus maturation or budding. The lower affinity 
binding site would not be occupied at intracellular calcium concentrations, but may 
become filled once the virus has budded into the extracellular fluid, possibly to 
increase the stability of the virus as shown by the DSF data.126 
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2.5 Circular Dichroism Spectroscopy 
 
In order to explore if the addition of calcium to hRSV-M has any significant change 
on the protein’s structure, it was subjected to circular dichroism spectroscopy. CD 
spectroscopy is a variant of UV-Vis spectroscopy, which relies on the use of 
circularly polarised light and its differing interactions with certain molecules. In the 
case of proteins, circular dichroism spectroscopy in the far UV range can be used to 
probe the secondary structure of a protein, but not tertiary or quaternary structure.129 
 
Light can be polarised into left-handed and right-handed polarised light. Each of these 
can interact with a medium in different ways. For circular dichroism spectroscopy, the 
change in absorbance of circularly polarised light per molecule is tested, giving 
equation 8 (where c is the concentration and l is the path length). For proteins, light is 
used in the far UV range (~180-260nm) since this covers the absorption band 
corresponding to amino acids. As a major constituent, it is mainly the n→π* (220nm) 
and π→π*(190nm) transitions of electrons in the amide bonds of the amino acids that 
absorb the circularly polarised light. As these bonds make up the backbone of the 
protein’s structure, the energy of these transitions is influenced by the geometry of the 
backbone, and hence the secondary structure of the protein. Changes in the structure 
of the protein backbone can therefore be detected and interpreted.130 
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Equation 8 
 
A circular dichroism measurement will report the different absorbance of polarised 
light in millidegrees, and this can be converted into mean residue ellipticity for 
analysis by equation 9. Mean residue ellipticity is used for proteins to give normalised 
values that can be compared between proteins of different sequences. 
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Equation 9 
 
Following a measurement, circular dichroism data can be analysed by comparing the 
obtained spectra with the spectra of other proteins of known 3D structure as 
determined by x-ray crystallography, and therefore making an estimate of secondary 
structural characteristics. For the following data, three different algorithms were used 
initially to analyse the data, Selcon3, Continll and CDSSTR. However, of these three 
only Continll provided a close fit to the data, and so is the only one shown here. The 
Continll algorithm relies on the assumption that different spectra assigned to different 
structural features can be linearly added together to calculate a fit for the experimental 
data. The algorithm takes a reference set of proteins with known secondary structure 
and spectra and compares them to the experimental data. If the match is considered 
good then that spectra is given a higher fraction of contribution to the final fit. Where 
Continll differs from other algorithms is that reference spectra with a poor fit are 
systematically deleted from the fitting as each iteration is carried out. 
 
The following experiments were carried out on hRSV-M, either in a weak buffer 
alone (1mM Tris-HCl) or with the addition of 1mM CaCl2. Spectra were recorded 
using a cuvette with pathlength 0.2cm and a range of collection of 180-240nm. The 
high tension voltage was monitored during the experiment, and any results obtained 
after the voltage went above 600V were disregarded as the noise in the data became 
too high.129 For analysis the spectra had a background reading subtracted and the 
values converted into mean residue ellipticity. For the fitting algorithms, reference 
protein set 10 was used (SMP56). This set contains 56 proteins of which 13 are 
membrane proteins. The large number of reference proteins helped to find a good 
fitting compared with smaller sets, and the addition of membrane proteins was used 
previously to help fit hRSV-M, likely because as a membrane binding protein it 
behaves in much the same way.39 
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Figure 24 - Circular dichroism spectra of hRSV-M in 1mM Tris-HCl, showing experimental 
values and spectra calculated with Continll 
 
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
190 195 200 205 210 215 220 225 230 235 240
Wavelength / nm
[θ
] m
rw
 /
 (
d
eg
.c
m
2
d
m
-1
re
si
d
u
e
-1
)x
1
0
3
Experimental Values - hRSV-M with calcium Calculated spectra - hRSV-M with calcium
 
Figure 25 - Circular dichroism spectra of hRSV-M in 1mM Tris-HCl and 1mM CaCl2, showing 
experimental values and spectra calculated with Continll 
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 Structural Feature (%) 
 α-Helix 
(regular) 
α-Helix 
(distorted) 
β-Sheet 
(regular) 
β-Sheet 
(distorted) 
Turn Irregular 
hRSV-M 
without 
calcium 
8.3 10.1 15.0 10.0 23.4 33.2 
hRSV-M 
with  
1 mM 
calcium 
7.5 9.8 15.8 10.5 22.9 33.4 
Table 7 – Secondary structural features of hRSV-M with and without calcium, calculated by 
Continll algorithm. 
 
 
The above results show that hRSV-M did not exhibit any significant change in 
secondary structure upon calcium binding. It can therefore be expected that calcium 
binding does not cause a great change in the protein’s 3D structure. Furthermore, the 
spectra obtained here gave the same secondary structure prediction as previous 
identified for hRSV-M in a phosphate based buffer.39 This indicates that the change in 
buffer conditions was also not changing the protein’s structure. 
 
2.6 Mass Spectrometry 
 
During experiments, samples of hRSV-M were regularly subjected to mass 
spectrometry analysis to check the purity of the samples. Since hRSV-M was first 
purified in our group, all mass spectra have shown the expected 29351 Da mass peak 
for the native hRSV-M, however it has also always shown a peak at +80 Da at 29431 
Da. While the identity of this extra mass has previously been theorised as either a 
bound metal or modification of an amino acid, it was never confirmed. 
 
During the experiments details in section 2.10, attempts were made to label hRSV-M 
with a fluorescent molecule to aid visualisation under microscope. While the final 
decision was made to use FITC, due to a stronger fluorescence, initially experiments 
were taken to label hRSV-M using  4-chloro-7-nitrobenzofurazan (NBD-Cl). This is a 
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reactive species, known to react with amino and thiol groups.131 On a protein this 
results in labelling on lysine and cysteine groups. When this procedure was carried 
out on hRSV-M, the results showed some interesting features, as detailed below. 
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Figure 26 - Structure of 4-chloro-7-nitrobenzofurazan (NBD-Cl) 
 
 
Figure 27 - Mass spectrum of native hRSV-M 
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Figure 28 - Mass spectrum of modified hRSV-M-NBD 
 
The mass spectrometry showed that NBD-Cl labelling had occurred on only one 
residue per protein molecule, with an additional peak at 29515 Da being present in 
figure 28 and absent in figure 27 corresponding to the addition of the NBD moeity, 
and so tryptic digest mass spectrometry was performed on the proteins by Dr Aruna 
Prakash of the mass spectrometry service at Durham. This involves the digestion of 
the protein into smaller peptides by using the peptidase trypsin, and then analysing the 
individual fragments to identify which have been modified. Only one fragment was 
identified as modified and is highlighted below, though the signals were weak so 
more may exist. 
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241 NWKHTATRFA IKPRED 
Figure 29 - Amino acid sequence of hRSV-M, with  NBD modified peptide highlighted 
 
Since the modified fragment contains only one lysine and one cysteine, the 
modification must have occurred on Lys-66. NBD-Cl has been shown to react quicker 
with cysteine residues, however afterwards it may transfer to a spatially nearby 
lysine.131, 132 UV spectrum data showed this may have occurred over time in this 
sample, with NBD-cysteine absorbing at 420 nm and NBD-lysine absorbing at 480 
nm (figure 30). In either case, the surprising feature of the mass spectra  is that the 
extra mass of the NBD moiety (+165 Da) could only be seen added to the first peak 
attributed to hRSV-M at 29351 Da and not to the latter peak with the extra +80 Da 
mass. This indicates that the change that gave the +80 Da found in a fraction of the 
native hRSV-M is blocking a change at Lys-66, and so they are likely the site of this 
modification. Unfortunately the tryptic digest was not able to identify directly a 
fragment with +80 Da, however the conflict with the additional NBD limits the 
possibilities for the modification. 
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Figure 30 - U.V absorption spectra for hRSV-M-NBD 
 
One theory was that the extra mass was due to bound metal ions, in particular an 
additional two calcium ions. While this does fit with the findings detailed previously 
for calcium bound to hRSV-M, this result makes it unlikely, since it would require 
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two tightly bound calcium ions while we now know one is weakly bound, and ICPMS 
data only showed one calcium bound per protein molecule after heavy loading of 
calcium. Furthermore, the NBD labelling experiments were conducted in the absence 
of calcium, and so it should not have interfered if this was the case. A more likely 
theory shown by this data is that the reactive cysteine residue has become modified 
and so is blocked from reacting with the NBD-Cl, and hence no transfer to lysine. A 
likely modification that may have occurred after purification is the oxidation of the 
thiol side group into either sulfenic acid (SOH) or sulfinic acid (SOOH) groups. This 
reaction occurs in the presence of hydrogen peroxide, and so can be seen when 
proteins are stored in water for a length of time133. Furthermore, in the mass spectra 
above several smaller peaks can be seen that correspond to the +16 Da or +32 Da that 
each of these oxidised species would add. The species present at 29381 Da 
corresponds to a single cysteine forming the sulfenic acid, while the main secondary 
peak at 29431 Da may result from all 5 cysteines present in hRSV-M being converted 
to the sulfenic form for a total of +80 Da. 
 
1. 2. 3.
 
Figure 31 - 1. Cysteine, 2. Sulfenic acid derivative, 3. Sulfinic acid derivative 
 
2.7 Interactions with lipids – Lipids of interest 
 
This work is a continuation of previous work in the group by Helen McPhee. Special 
thanks should also be given to masters student Amy Fry for helping collect some of 
the isotherms involved. 
 
A number of experiments were carried out in order to observe the behaviour of hRSV-
M interacting with lipids, as detailed later in this chapter. The lipids used were chosen 
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based on previous experiments, and on literature suggesting they may be interesting 
targets for hRSV-M. 
 
Typical eukaryotic cell membranes consist of glycerophospholipids, sphingolipids 
and sterols. Glycerophospholipids are the major species of lipid in cell membranes, 
although this can divided into many types. They consist of a glycerol backbone with 
two fatty acid tails and a polar head group. Sphingolipids are similar, except the 
backbone is consists of a sphingosine moiety and hence only have one additional fatty 
acid chain and are usually found in much smaller amounts. Sterols tend to be smaller 
planar structures that are found intercalating between the other lipids, and modulating 
the structure of the membrane. 
 
Among lipids, the nature of fatty acid tails are considered to be most involved in 
changing the membrane’s fluidity. The fatty acid tails resides within the hydrophobic 
core of the membrane bilayer and so changes in their length and degree of saturation 
have a large effect on membrane fluidity through changing the packing of the lipids. 
This makes the selection of fatty acid tail lengths for experiments crucial to determine 
the layer’s properties. While tails lengths vary from C6 to C24, the most common 
chain lengths found in mammalian cell membranes are C14, C16 and C18. These all 
exist in the gel phase, and so can be used to study a fluid membrane, as is seen in 
living systems.134 For these experiments, a range of C16, C18 and mixed lipids were 
used. 
 
The head groups of phospholipids are very important for studying lipid interactions, 
since it is known hRSV-M interacts with the surface of a membrane.47 
Phosphatidylcholines were the most frequently used lipid, since they are the most 
common found in nature, both in lung cell membranes and in virus envelopes related 
to hRSV. These small neutral lipids form a useful scaffold for other lipid species to be 
embedded in. The other main focus of this project was phosphatidylserine based 
lipids. This lipid head group is highly negatively charged and has been included 
because it has been previously identified as involved in the binding of several other 
viral proteins to lipid membranes.135 It is also a major component of cell membranes, 
as detailed below, and the presence of a large positively charged surface on hRSV-M 
may indicate an interaction with negatively charged patches on the membrane. 
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A combination of sphingomyelin and cholesterol were also studied, both in mixtures 
and separately. Mixture of sphingomyelin, cholesterol and a phosphatidylcholine 
based lipid are known to produce phase separation, creating liquid ordered domains of 
sphingomyelin and cholesterol separate from liquid disordered domains of 
phosphatidylcholine based lipids. These form the basis of lipid microdomains, often 
called lipid “rafts”, found in cell membranes.136 These microdomains have been 
identified as a location for viral assembly and budding for several different viruses, 
including hRSV.19, 137, 138 
Lipid Component % of total lipids 
Phosphocholine 34 
Phosphoethanolamine 32 
Phosphoserine 13 
Phosphoinositide 9 
Sphingomyelin 11 
Table 8 - Phospholipids found in the plasma membrane of human lung tissue139 
 
 
Fatty Acid Chain % total fatty acids 
16:0 – palmitoyl 4 
18:0 – stearoyl 20 
18:1 – oleoyl 40 
18:2 – linoleoyl 2 
18:3 - linolenoyl 8 
Table 9 - Fatty acid composition of lipids from A549 lung epithelial cell plasma membranes140 
 
 % of phospholipids 
Virus family PC PE SM PS PI 
Paramyxoviridae 8-53 10-41 12-30 2-17 0-11 
Rhabdoviridae 16-38 20-34 16-31 7-20 0-10 
Orthomyxoviridae 10-39 12-45 16-23 7-22 0-8 
Togaviridae 21-49 19-35 7-29 9-21 0-9 
Retroviridae 16-30 26-42 22-33 12-17 0-4 
Table 10 - Percentage of phospholids found the the envelope of several families of RNA viruses.141 
PC = Phosphocholine, PE = Phosphoethanolamine, SM = Sphingomyelin, PS = Phosphoserine, PI 
= Phosphoinositide 
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Figure 32 - Lipids used for experiments with hRSV-M. Top to bottom, 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), 1,2-Dioleoyl-sn-glycero-3-Phosphatidylcholine (DOPC), 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-Dipalmitoyl-sn-glycero-3-phosphoserine 
(DPPS), Cholesterol, Sphingomyelin C16. 
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2.8 Langmuir Adsorption Isotherms 
 
2.8.1 Theory 
 
When studying the effect of a protein on lipids, it would be advantageous to be able to 
conduct experiments on a bilayer system. However in practice these experiments are 
often difficult to perform, with problems in obtaining a stable bilayer in a manner that 
can be probed for quantifiable data. As such, it is often necessary to use a monolayer 
of lipids as a model system. A monolayer is a useful system since it can be formed 
easily at an air-water interface due to the amphiphilic properties of lipids, and a 
bilayer can be approximated to two coupled monolayers joined by their hydrophobic 
surfaces.142 Lipids applied to the surface of water will spontaneously form a 
monolayer. This is because the polar head groups of lipids will orientate themselves 
towards the water layer, while the hydrophobic tails will be repulsed by the polar 
liquid surface. The properties of monolayers at the interface of air and water have 
been found to mimic the properties of a bilayer closely.143 
 
Figure 33 - A lipid monolayer on a Langmuir-Blodgett trough (©KSV Nima) 
 
To study the effect of hRSV-M on a lipid monolayer, a Langmuir-Blodgett Trough 
was used. The trough is composed of a hydrophobic surface of Teflon, and is filled 
with a buffer solution to act as the subphase. Two moveable Delrin barriers sit at the 
surface level to vary the exposed area of the subphase surface. The monolayer is 
formed by the addition of the lipids dissolved in a volatile solvent to the surface. As 
the solvent evaporates the monolayer is formed. The surface pressure (Π) of the 
surface can be monitored using a Wilhelmy plate attached to a microbalance. 
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Figure 34 - The Langmuir trough (KSV Nima) used in these experiments 
 
 
 
Figure 35 - A Wilhelmy plate, showing the contact angle (θ), contact surface (l) and downward 
force applied (F) 
 
 
The surface pressure can be found by the forces acting upon the Wilhelmy plate. The 
forces acting on the plate are the surface tension (γ) downwards, the Archimedes 
buoyancy (A), and its weight (P). These combined with the width and thickness (w + 
t) of the Wilhelmy plate and contact angle (θ) give the following equation.144 
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AtwPf −++= θγ cos)(2  
Equation 10 
 
When the Wilhelmy plate is completed hydrated, the contact angle, θ, is 0° and so 
cosθ=1. The thickness of the Wilhelmy plate can also be considered to be negligible 
compared with the width when calculating the perimeter. These give the equation: 
AwPf −+= γ2  
Equation 11 
 
The weight (P) and buoyancy (A) are constant during an experiment, the change in 
surface tension can be modelled as: 
Π−=−=∆ wwf 2)(2 0γγ  
Equation 12 
 
Where Π is the change in surface pressure relative to the surface pressure of a clean 
subphase (γ0), which is 71.97 mN/m. Once measurements have been made, a plot of 
surface area per molecule against surface pressure can be made to give the 
pressure/area isotherm. From this we can see how the monolayer properties change 
with a reduction in area per molecule. 
 
When analysing the data obtained, we want to look at the surface excess of the 
components in the monolayer. This is a measure of how much greater the material has 
an affinity for the interface over the bulk subphase. For a two component system this 
is represented by the Gibbs absorption isotherm, and is given by the following 
equation: 
02211 =Γ+Γ+ µµγ ddd  
Equation 13 
 
Where Γ is the surface excess (defined as ns/s, the concentration at the surface over 
the area) and µ is the chemical potential. For a system in which the surface excess of 
one component, the solvent in this case, is reduced to zero the equation can be written 
as : 
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22 µγ dd Γ=  
Equation 14 
 
By taking the relationship for µ: 
2
0
22 ln aRT+= µµ  
Equation 15 
 
Where a is the activity and 02µ is the standard chemical potential, then equation 14 can 
be rewritten as: 
)
ln
(
1
2
2
ad
d
RT
γ
−=Γ
 
Equation 16 
 
This is the Gibbs adsorption isotherm. This allows us to calculate the surface excess 
given the change in surface tension.145 
 
However, when studying a protein binding or inserting into a monolayer at the 
interface, this equation is not detailed enough to give an adequate model. Other 
models have been derived from the Gibbs adsorption isotherm which can be used for 
more complex systems like protein-lipid interactions. The first is the ordinary Pethica 
equation, which extends the adsorption isotherm to a system with one soluble 
component (the protein) and one insoluble component (the lipid monolayer) and is 
defined as: 
)1(
)
ln
(
1
2
2
1 Θ−
Γ
=
∂
Π∂ RT
c
θ  
Equation 17 
 
Where Θi is the monolayer coverage (Γi/Γ∞i) and ci is bulk concentration of the 
soluble component. If the monolayer can be described as an ideal mixture of the two 
components, then it can also be described by a generalised Szyszkowski-Langmuir 
equation: 
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εω
RT
 
Equation 18 
 
With ωε, the mean molar area being: 
21
2211
Γ+Γ
Γ+Γ
=
ωω
ωε  
Equation 19 
 
Differentiating equation 18 with respect to Θ2 (and assuming Θ1 and ωε are constant) 
gives: 
212 1
1
)(
1 Θ−Θ−
⋅=
Θ∂
Π∂
ε
θ
ω
RT
 
Equation 20 
 
Given this relationship between the Pethica equation (17) and equation 20, they can 
be combined to give: 
2
212
1
)1(
1
ln Θ
Θ−Θ−Θ
Θ−
= dcd
 
Equation 21 
 
That can be integrated to give a modified Langmuir binding isotherm:145 
)1( 21
2
2
Θ−Θ−
Θ
=Kc
 
Equation 22 
 
Where K is the absorption equilibrium constant for an soluble surfactant and an 
insoluble monolayer. This equation will be used in the fitting of experimental data 
later. 
 
Langmuir isotherms were carried on using a subphase of PBS, the surface of which 
was thoroughly cleaned before each experiment. The surface pressure was first taken 
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and used as a base level for the experiments. Protein was then pipetted onto the 
subphase surface, followed by the lipids dissolved in chloroform. This was then 
allowed to equilibrate for 20 minutes before beginning compression of the monolayer. 
 
2.8.2 hRSV-M only monolayer 
 
hRSV-M was first applied to a clean subphase surface, in order to see how it behaves 
at the air-water interface. An individual aliquot of hRSV-M was added to the surface 
and left for 20 minutes to equilibrate. The surface pressure was then recorded and a 
further aliquot was added. This was repeated over a range of concentrations to 
determine how the pressure depends on protein concentration. The following equation 
can then be used to fit the data and calculate important parameters for the protein.146 
lvN
BB
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o
lv
lv
CC
γ
γγ
γ ′+
+
′−
=
Π
)
)ln/(ln1
(
2/  
Equation 23 
Where olvγ  and lvγ ′  are the lower and upper concentration asymptotes (giving the 
surface pressure for the clean subphase and protein saturated surface respectively), CB 
is the protein concentration of the subphase, 2/ΠBC is the protein concentration at half 
the maximum change in surface pressure, and N is a description of the gradient of this 
section.147 Experimental results are displayed below: 
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Figure 36 - Surface pressure as a function of protein concentration for hRSV-M additions to an 
air-water interface on a Langmuir trough. Data subsequently fit using equation 23. 
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2/Π
BC  1902 pM 
Πmax 8.85 dyn/cm 
Γ 6.78 pmol/cm2 
Area per molecule 2447 Å2 
Table 11 - values for hRSV-M calculated from data fitting in figurer 36 
 
This data concurs with that reported previously.47 This shows that the change in 
purification method for hRSV-M has not altered the surface properties of the protein. 
A pressure/area isotherm was also ran on a saturated surface of hRSV-M. While most 
surface active species cannot go above the equilibrium spreading pressure without 
collapsing back into the subphase, the results here show that hRSV-M is able to attain 
a meta-stable state and reach much higher pressures. A collapse point for the layer 
was not reached even when compressed to the smallest area the trough could make. 
When the monolayer was allowed to relax the pressure dropped back to the spreading 
pressure. This suggests that hRSV-M is able to closely pack together and form a more 
condensed phase.148 
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Figure 37 - Pressure/Area isotherm for a saturated surface of hRSV-M 
 
2.8.3 hRSV-M on lipid monolayers 
 
The data was obtained as the effect of monolayer compressions using different lipid 
compositions and for a range of different hRSV-M subphase concentrations. This 
work is a continuation of earlier isotherms published in Ref.1 (McPhee et. al.) 
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Figure 38 - Pressure/Area isotherm for 7ug Cholesterol with hRSV-M additions (% by mass, 
molarity in brackets) 
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Figure 39 - Pressure/Area isotherm for 4ug Sphingomyelin with hRSV-M additions (% by mass, 
molarity in brackets) 
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Figure 40 - Pressure/Area isotherm for 7ug Cholesterol / Sphingomyelin (1:1 w/w) with hRSV-M 
additions (% by mass, molarity in brackets) 
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Figure 41 - Pressure/Area isotherm for 4ug DOPC + DPPS (4:1 w/w) with hRSV-M additions (% 
by mass, molarity in brackets) 
 
All of the above isotherms show that for an increase in the subphase concentration of 
hRSV-M, there is an increase in the initial surface tension of the monolayer. They 
also all show that for a given subphase concentration of hRSV-M, the monolayer 
becomes saturated and no change is seen for further amounts of protein added. 
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The isotherm with cholesterol alone shows that for the low protein amounts (0.1-1%) 
the protein is partitioning into the monolayer. As the area is decreased, hRSV-M is 
then forced out of the monolayer, giving the plateau seen at approx 8.85 mN m-1. This 
is the same as the equilibrium spreading pressure for hRSV-M alone. Once the protein 
has all been forced out at around 50Å area per lipid, the isotherm reverts to its lipid-
only state. For higher amounts of protein, (>2.5%), it is likely that the protein has 
formed the majority of the monolayer, and so the cholesterol has not been able to fit 
into the monolayer and has been removed into the subphase. This results in the 
isotherms appearing to be similar to that for a saturated protein layer alone.47 
 
The isotherm with sphingomyelin alone shows much of the same features, with a 
plateau at 8.85 mN m-1 for low protein concentrations. However, it appears that to all 
the protein has been forced out, since the isotherm shifts towards a higher area per 
lipid molecule, indicating that HRSV-M has intercalated with the lipid. This trend can 
be seen across all protein concentrations, with the plateau only disappearing when the 
starting pressure is higher than it. This indicates that an interaction is occurring 
between hRSV-M and sphingomyelin. The increase in the surface area per lipid 
molecule relative to the surface pressure indicates that a more diffuse monolayer is 
being formed, one comprising both sphingomyelin and hRSV-M. 
 
Figure 40 showing the isotherm involving a lipid mix of cholesterol and 
sphingomyelin does not have the same plateau shown in the others. This indicates that 
when a mixture of these lipids are used hRSV-M is not forced out of the monolayer as 
it is compressed, and stays as a part of it after insertion. Increased protein 
concentration gives a much higher surface pressure at larger areas per lipid molecule, 
showing that the hRSV-M and lipids are interacting with each other. Furthermore, the 
collapse pressure of the monolayer (Πmax) increases steadily from 38.14 mN m-1 for 
the lipid mixture alone to 50.22 mN m-1 at 5% hRSV-M and above. This shows that 
the monolayer comprising lipid and protein is more stable than the monolayer of lipid 
alone, resisting collapse until a higher pressure is applied. 
 
These three isotherms were carried out to compare with an earlier isotherm for a 
ternary mixture of DOPC/Sphingomyelin/Cholesterol, a mixture that creates domains 
of Lo and Ld phases..
47 This showed a plateau at the same pressure (8.85 mN m-1) 
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indicating that protein was forced out of the monolayer, but then showed a decrease in 
pressure for a given area, showing the addition of protein causing the monolayer to 
condense. This was interpreted as the protein being forced out of the liquid disordered 
areas of the monolayer comprised mainly of DOPC, while causing a condensation of 
the ordered domains of the monolayer. The results here appear to show that this 
behaviour is unique to this ternary mixture, since combinations of the individual 
components failed to replicate this behaviour. 
 
The isotherm for the DOPC/DPPS (4:1) mixture shows a large increase in the 
pressure relative to area per molecule, with the Πmax being reached at between 2-5%. 
This indicates insertion of the protein into the monolayer, and a more stable 
monolayer being formed, with hRSV-M having a high affinity for this partitioning. 
This may be indicative of a specific interaction between hRSV-M and 
phosphatidylserines. 
 
Cross sections at a constant area per lipid molecule through these isotherms were 
taken and fit to the modified Langmuir binding isotherm (equation 22). The area per 
lipid molecule for each was chosen to be above any phase transition pressures. The 
isotherm for a cholesterol monolayer could not be fit by this method, since its 
behaviour was significantly different at higher and lower protein concentrations. 
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Figure 42 – Adsorption isotherms corresponding to cross sections of pressure / area isotherms at 
a fixed area per lipid molecule as a function of CB. Top left, Sphingomyelin A = 100 Å
2 per lipid 
molecule, ωΣ = 24 Å
2. Top right, SM/Chol A = 65 Å2 per lipid molecule, ωΣ = 31 Å
2. Bottom, 
DOPC/DPPS A = 125 Å2 per lipid molecule, ωΣ = 45 Å
2 
 
Lipid CB at surface 
saturation / nM 
Adsorption Equilibrium 
Constant K / M-1 
Sphingomyelin ≥ 2 2.72 x 10-8 
Sphingomyelin/Cholesterol 
1:1 
≥ 4.5 1.20 x 10-8 
DOPC/DPPS 4:1 ≥1.5 3.56 x10-8 
Table 12 - Summary of parameters for hRSV-M adsorbing to lipid monolayers 
 
The data collected show that a monolayer containing DOPC/DPPS has a greater 
adsorption equilibrium constant and a low surface saturation, and therefore an 
increased affinity of hRSV-M for this monolayer. The SM/Chol monolayer appears to 
result in a lower affinity than a monolayer of SM alone, with a lower CB of 4.5 nM 
versus 2 nM, however this may be the result of different modes of interaction, with 
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hRSV-M intercalating into the sphingomyelin monolayer as opposed to it interacting 
with the surface of a SM/Chol monolayer. 
 
2.9 Brewster Angle Microscopy 
 
It is possible to directly visualise the surface of a Langmuir film using a technique 
called Brewster angle microscopy (BAM). When polarised light is directed onto a 
liquid surface, the light can be refracted into the liquid or reflected away. The amount 
of light that goes in each direction depends on the incident angle, due to the change in 
refractive index of the air to water transition. At a unique angle, called Brewster’s 
angle, the reflected component is zero and so a camera pointed at the surface (also at 
Brewster’s angle) will detect no signal off the subphase surface. This angle is 
determined by Snell’s law, and for water is approximately 53°.149 
12 /tan nn=α  
Equation 24 - Snell's law. α is Brewster’s angle, n2 and n1 are the refractive index of the subphase 
and air respectively 
 
 
Figure 43 - Schematic for the Brewster angle microscope setup used 
 
When the surface of the subphase is changed, for example by the addition of a 
monolayer, the refractive index for this boundary now changes as well. This leads to 
light now being reflected off the monolayer, while any exposed subphase remains 
dark. Since the refractive index of the surface monolayer is dependant on its structure, 
the images produced can reveal structural features of the monolayer. In the following 
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experiments it can also reveal any changes in structure caused by additions of hRSV-
M. 
 
Brewster angle microscopy has several advantages over other techniques for 
visualising protein-lipid interactions, such as fluorescent microscopy and atomic force 
microscopy. The technique can be carried out by on unmodified proteins and lipids, 
unlike traditional fluorescent microscopy which require additional fluorescent tags to 
be added. It also allows the whole layer to be viewed simultaneously, while 
fluorescent markers may partition differently between different phases that are 
formed. It is also a much more time sensitive experiment than atomic force 
microscopy, which requires the sample to stay stable for a while for each image to be 
acquired, while BAM is acquires images in real time.150 
 
All experiments were carried out on the same trough as the previous isotherm 
experiments. Once the subphase was added to the trough, the clean up polariser and 
mirror angles were adjusted till zero reflection was detected by the camera. These 
settings were not changed for the remainder of the experiment. Protein and lipids were 
then applied in the same manner as for Langmuir isotherms. These experiments were 
only carried on using DOPC/DPPS (4:1 w/w) as a lipid mixture. 
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Figure 44 - BAM images from isotherm of hRSV-M compression. top left = clean subphase, top 
right = hRSV-M at Πmax (8.9 mN m-1), bottom left = hRSV-M at metastable 26.3 mN m-1, bottom 
right = hRSV-M layer after disruption with pipette tip 
 
The images of hRSV-M alone show that it readily forms a homogenous monolayer on 
the subphase surface, as seen by the change in contrast of the images. When the 
monolayer was disrupted with a pipette tip (figure 44 - bottom right), distinct edges 
could be seen where the monolayer was damaged. These tears would slowly close and 
return to the previous state, over a period of 20-30 minutes. This suggests that hRSV-
M forms a fairly condensed layer at the surface that only equilibrates slowly with the 
subphase. 
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Figure 45 - BAM images from isotherm of 7µg DOPC/DPPS (4:1 w/w). Top left = clean subphse, 
top right = monolayer at Π=7.1 mN m-1, bottom = monolayer at Π=37.2 mN m-1 
 
These images from lipid only isotherms show that while a condensation of the lipids 
can be seen as they change phase at higher pressures, they are still featureless 
homogenous surfaces. 
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Figure 46 - BAM images from isotherm of 7µg DOPC/DPPS (4:1 w/w) with addition of 10% 
(w/w) hRSV-M (28.7 nM). Top left = monolayer at Π=21.4 mN m-1, top right = monolayer at 
Π=30.6 mN m-1, bottom left = monolayer at Π=37.1 mN m-1, bottom right = monolayer at Π=40.1 
mN m-1 
 
The addition of hRSV-M to the monolayer before compression dramatically changes 
the look of the monolayer. As the pressure is increased small (<50 µm) domains are 
seen to be formed, with them being most apparent close to the collapse pressure. 
Given the contrast for these domains is much greater than seen in the lipid only BAM 
images, it is likely that hRSV-M is involved in these domains. This may be the 
protein intercalating between the lipids, or binding to the head-group surface of the 
monolayer. To distinguish between these two possibilities, a DOPC/DPPS monolayer 
was formed at a fixed pressure above the equilibrium spreading pressure of hRSV-M 
(8.85 mN m-1). At a higher pressure we would not expect to see the protein 
penetrating into the monolayer, however it would still be able to interact with its 
surface. All additions of protein were given 30 minutes to equilibrate. The pressure of 
the surface did not change significantly during the experiment. 
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Figure 47 - BAM images of a 7µg DOPC/DPPS (4:1 w/w) monolayer at a fixed surface pressure 
of 23.2 mN m-1, followed by additions of hRSV-M to the subphase. Top left = lipid only, top right 
= with 2% hRSV-M (3.28 nM), middle left = 5% hRSV-M (8.2 nM), middle right = 10% hRSV-
M (16.4 nM), bottom = 25% hRSV-M (41 nM) 
 
These images show the same small domain patterning as for the isotherm runs. This 
suggests that hRSV-M is interacting with the polar head groups of the lipids and 
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clustering them into small patches. These patches may indicate a clustering of 
proteins at each spot, possibly through protein oligomerisation. 
 
2.10 Fluorescent tagging of hRSV-M 
 
For a following experiment, it was necessary to attach a fluorescent moiety to hRSV-
M so it could be visualised by microscopy. Initially an NBD moiety was used, 
however the fluorescent signal from the tagged protein proved to be too weak, and so 
this was replaced with a fluorescein isothiocyanate (FITC) tag. FITC is a commonly 
used fluorescent dye, due to its ready reactivity with nucleophiles such as amines, and 
its high quantum yield in solution. It is excited at 495 nm and emits at 519 nm, giving 
it a green colour.151 
 
Figure 48 - Structure of fluorescein isothiocyanate 
 
hRSV-M was reacted with FITC in a 1:1 manner, though the final labelling amount 
was calculated at between 25-40% by U.V spectroscopy (data not shown). Labelling 
was confirmed by SDS-Page gel electrophoresis, with the resulting gel being imaged 
in a fluorescent scanner set for green emissions. 
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Figure 49 - SDS Page gel of FITC labelled hRSV-M. Left image = Coomassie stained gel with 
normal photograph. Right = Fluorescent scanned image at 520 nm. Lane 1 contains size markers, 
lane 2 is native hRSV-M, lane 3 is hRSV-M-FITC 
 
As a check that the addition of FITC to hRSV-M had not dramatically changed its 
properties, it was subjected to the same Langmuir isotherm experiment as hRSV-M 
alone (see section 2.8.2) to determine if its surface active properties had changed 
significantly. The results are detailed below. 
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Figure 50 - Surface pressure as a function of protein concentration for hRSV-M-FITC additions, 
data was fit to equation 23 
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Parameter hRSV-M hRSV-M-FITC 
2/Π
BC  1902 pM 1292 pM 
Πmax 8.85 dyn/cm 9.27 dyn/cm 
Γ 6.78 pmol/cm2 4.20 pmol/cm2 
Area per molecule 2447 Å2 3956 Å2 
Table 13 -  values for hRSV-M calculated from fitting in figure 50 
 
While there have been some changes in the properties of hRSV-M-FITC, overall they 
are very small. A slight increase for affinity for the air-water interface is a surprising 
result though, since FITC is water soluble and would not have been expected to have 
this effect. 
 
2.11 Giant Unilamellar Vesicles and confocal microscopy 
 
Liposomes are often used as model systems for membrane binding. This is because 
they form bilayer systems with the same lipid structure as cell membranes and we can 
control their size and hence membrane curvature. However, these liposomes are can 
only be made to diameters ≤ 5 µm in size, while the average humans cell is between 
10-100 µm. This leads to liposomes having a far greater membrane curvature than real 
cell membranes and makes them too small to view by microscopy methods. 
Especially when using membranes that exhibit multiple phase behaviours, it is 
important to be able to visualise different domains so if there are any specific 
interactions or localisation of proteins to the membrane we can see which domains 
were involved. To achieve this, we designed a method modified from Angelova et. al. 
to generate Giant Unilamellar Vesicles (GUVs).152 GUVs are much like liposomes, 
but show a diameter distribution of 1-300 µm, and are therefore a much better mimic 
of a cell’s plasma membrane due to similar curvature. Along with this, the increased 
size means that it is now possible to visualise the vesicles using phase contrast 
microscopy and, if appropriately labelled, by fluorescent microscopy. 
 
GUVs can be formed through several different methods. While a quick method is to 
form them out of a surfactant / water mixture, this leaves the surfactant contaminating 
your experiments, and is prone to producing multi lamellar structures. 153, 154 An 
alternative electroformation method was chosen since it has been shown to generate 
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very uniform GUVs and reduce the number of Multi Lamellar Vesicles (MLVs), 
while still being relatively easy to carry out.153 This is modification of a simple 
hydration method, where a dried lipid film is slowly hydrated causing the lipids to 
slowly bud off the surface and form liposomes. This is modified by the application of 
an alternating electric current, which is believed to help overcome the van der Waals 
forces that otherwise hold the lipids as a layer on the glass. 
 
Figure 51 - Schematic of lipid hydration / electroformation of GUVs. ©Creative Commons 
 
This method does have some drawbacks, for example it is unable to form GUVs with 
a high content of charged lipids, but was suitable for these experiments. For the 
formation of GUVs by this method, 1-10 µg of lipids are first dried onto conductive 
indium tin oxide (ITO) coated slides. A well is created between two slides using a 
nitrile O-ring, and is filled with a weakly buffered sucrose solution (5 mM sodium 
phosphate, 300 mM sucrose, pH 7.4). A weak buffer must be used since it has been 
found that high salt conditions inhibit GUV formation.152, 155 An electric current is 
then applied across the well. The voltage is increased from 0.1V to 1.2V at 10 Hz in a 
sine waveform over ten minutes, and then maintained at 1.2V for 3 additional hours. 
This results in GUV formation; however most will still be attached to the glass 
surface. A final step of 1.2V at 5 Hz in a square waveform for 20 minutes is used to 
detach the GUVs. This creates GUVs with an internal solution of sucrose. While this 
process is suitable for single component lipids with a Tm below room temperature, 
lipids with a higher Tm and mixed systems that phase separate require that the sample 
is heated during the procedure. For this, an oven was constructed, and the GUV 
apparatus was heated to 70°C for the duration of the electroformation, followed by 
slowly cooling to room temperature. This slow cooling process is required so that any 
phase separation may develop correctly, cooling too quickly has been shown to stop 
phase development.156 
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Figure 52 - A = schematic of GUV formation chamber, B = Sample holder for GUV viewing by 
microscopy. 
 
 
Figure 53 - Photograph of assembled GUV electroformation apparatus 
 
Once the GUVs have been formed, the sample has to be prepared for observation by 
microscopy. The sample holder consists of a glass cover slip (passivated with bovine 
serum albumin) attached to a small Teflon lined well, so the sample can be loaded 
into the well and observed from underneath by the microscope. The well is first filled 
with a buffered glucose solution that is matched in osmotic strength by the sucrose 
solution used for forming the GUVs (5 mM Sodium Phosphate, ~280 mM Glucose, 
pH 7.4). 5µl of the GUVs can then be added to this solution to be viewed. The 
difference in density of glucose and sucrose solutions means that the GUVs will sink 
to the bottom of the well, resting on the glass surface. Experiments with hRSV-M 
instead had the osmotic strength of the glucose and sucrose solutions matched with a 
5 µM hRSV-M solution in 5 mM Sodium phosphate (pH 7.4). This was then added to 
the sample well as required. 
 
Confocal fluorescent microscopy was used to visualise the GUVs. This form of 
microscopy uses a pinhole in the apparatus in order to block any light from outside 
the focal point. This means that thin sections (< 5 um) through the sample can be 
viewed. This is very useful for viewing GUVs since they are spherical, and so this 
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technique allows us to view a cross section through the vesicle. In order to visualise 
the GUVs and hRSV-M under the microscope they had to be fluorescently tagged. 
hRSV-M-FITC was used for protein additions, produced as detailed in section 2.10. 
For labelling the GUVs a rhodamine B labelled lipid, 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) ammonium salt, was used 
(henceforth called Rh-PE). This fluoresces in the red region and so is a good 
counterpart to using a green labelled protein. It has also been shown to partition to 
different phases of lipid bilayers with different affinities. It shows a preference for Ld 
phases, and so we can use this lipid to distinguish different phases in a phase 
separated GUV, such as those produced from DOPC/Sphingomyelin/Cholesterol 
(1:1:1 molar). For experiments without protein, a green labelled lipid 1,2-diphytanoyl-
sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) ammonium 
salt, (henceforth called NBD-PE) was also used to visualise the whole GUV. This 
lipid does not show any preference for phase partitioning.157 Fluorescently labelled 
lipids were used in such low concentrations (0.1 mol%), that their effect on membrane 
properties would be negligible. 
 
 
Figure 54 – Top: Structure of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) ammonium salt. Bottom Structure of 1,2-diphytanoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) ammonium salt. 
 
The confocal microscope used for image collection was either a Biorad Microradience 
2000 or a Zeiss 510 Meta.  Rh-PE was excited using a 543.365 nm GreenNe Laser 
and fluorescence detected with a photomultiplier tube with an E570nm Longpass 
filter. NBD-PE and hRSV-M-FITC were excited using a 488.0 nm Argon Laser and 
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fluorescence detected with a photomultiplier tube with a HQ530/60 nm Bandpass 
filter. Images presented here are a representative selection from many taken in each 
sample, and have been given false colour relative to their channel. 
  
 
2.11.1 Lipid only GUVs 
 
GUVs consisting of DOPC only and DOPC/Sphingomyelin/Cholesterol (1:1:1 molar) 
were first produced to check the quality of produced GUVs and if phase separation 
was being achieved.  
 
 
Figure 55 - Confocal image of a DOPC GUV with Rh-PE, red channel 
 
 
Figure 56 - Confocal image of DOPC/SM/Chol (1:1:1) GUV with NBD-PE and Rh-PE. Left = 
Green channel, Right = Red channel 
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These images show that the GUVs produced were unilamellar and of a suitably large 
size. In particular, the DOPC/SM/Chol mixture is shown to phase separate well, with 
the Rh-PE lipid partitioning into the disordered phase. 
 
2.11.2 GUVs with hRSV-M-FITC added 
 
Figure 57 - Confocal image of DOPC GUV with 5µM hRSV-M-FITC. Top left = Green channel 
(M-FITC), Top right = Red channel (Rh-PE),  Bottom Left = Merged 
 
For GUVs of DOPC, no interaction of HRSV-M with the GUV could be observed. It 
can also be seen that hRSV-M-FITC is staying outside the GUV and is unable to cross 
the bilayer, as seen by the lack of green fluorescence inside the GUV. 
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Figure 58 - Confocal image of DOPC/SM/CHOL (1:1:1) GUV with 5 µM hRSV-M-FITC. Top 
left = Green channel (M-FITC), Top right = Red channel (Rh-PE), Bottom = Merged 
 
GUVs consisting of DOPC/SM/Chol (1:1:1 molar) in figure 59 showed some 
interaction with hRSV-M. Small spots of hRSV-M-FITC could be seen on the surface 
of the GUVs, but only on the rhodamine labelled Ld phase. The spots are slightly 
larger than would be expected for a single layer of hRSV-M-FITC, suggesting that 
these may be small aggregates that are interacting with the DOPC/Chol phase. 
However overall little interaction was seen. 
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Figure 59 - Confocal image of DOPC/DPPS (4:1) GUV with 5µM hRSV-M-FITC. Top left = 
Green channel (M-FITC), Top right = Red channel (Rh-PE),  Bottom Left = Merged 
 
GUVs of DOPC/DPPS (4:1 w/w) showed a strong interaction with hRSV-M-FITC as 
seen in figure 59. The GUVs were not phase separated in the absence of protein, 
however upon addition of hRSV-M patches could be seen on the surface where 
hRSV-M had bound and the Rh-PE dye had been mostly excluded. This suggests that 
these areas have changed phase from a disordered to a more ordered phase due to 
hRSV-M binding the lipids. It is possible that hRSV-M is clustering the DPPS 
component of the membrane together, creating a raft rich in DPPS. 
 
In order to investigate this behaviour, two further mixtures of lipids were used. The 
first was DOPC/DPPC/Chol/DPPS (1:1:1:1 molar). This mixture might be expected to 
phase separate naturally, into a DOPC Ld phase and a DPPC/Chol/DPPS Lo phase.
158 
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Figure 60 - Confocal image of DOPC/DPPC/Chol/DPPS (1:1:1:1) GUV with 5µM hRSV-M-
FITC. Top left = Green channel (M-FITC), Top right = Red channel (Rh-PE),  Bottom Left = 
Merged 
 
Unfortunately the GUVs were not seen to naturally phase separate. This may be due 
to the relatively decreased amount of cholesterol compared with a DOPC/DPPC/Chol 
(1:1:1 molar) mixture. However the GUVs did still show the same behaviour with 
hRSV-M as the DOPC/DPPS (4:1) GUVs, with the binding of hRSV-M resulting in 
an exclusion of the Rh-PE dye seen in figure 60. 
 
The final mixture tested was for GUVs consisting of POPS/SM/Chol (1:1:1 molar). 
This was devised to see what effect having the phosphatidylserine component in a 
largely Lo phase would be.
159 Due to changes observed over time, two figures are 
provided below showing changes. 
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Figure 61 - Confocal image of POPS/SM/Chol (1:1:1) GUV with 5µM hRSV-M-FITC, at Time = 
2 minutes. Top left = Green channel (M-FITC), Top right = Red channel (Rh-PE),  Bottom Left = 
Merged 
 
 
Figure 62 - Confocal image of POPS/SM/Chol (1:1:1) GUV with 5µM hRSV-M-FITC, at Time = 
10 minutes. Top left = Green channel (M-FITC), Top right = Red channel (Rh-PE),  Bottom Left 
= Merged 
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Within the first few minutes of the experiment, hRSV-M-FITC can be seen binding 
over the whole surface of the GUV. This strong interaction may be due to the 
increased ratio of phosphatidylserine present in this lipid mixture (33%). However, 
after a period of ten minutes, its was observed that small concentrated spots of hRSV-
M-FITC were appearing over the surface, as seen in figure 62. These were typically 
<1 µm in size, and appeared to be randomly distributed. These may possibly be the 
formation of oligomers of hRSV-M at the surface following lipid binding. 
 
2.12 Lipid Nanodiscs 
 
While the previously used methods for studying protein-lipid interactions give a great 
deal of information, they all have several drawbacks in common. They all involved a 
large lipid surface, and studying the bulk interactions between this and the protein of 
interest. In order to study the protein-lipid interaction at a smaller scale, lipid 
nanodiscs were used. 
 
A class of proteins, the plasma lipoproteins, were found to bind small liposomes in the 
blood as a method of lipid transport. When extracted it was found that with synthetic 
lipids they would form small disc structures, consisting of a ring of protein 
surrounding a central lipid bilayer.160 These proteins were thus used as a basis for 
creating synthetic proteins with similar properties. The predominately α-helical C-
domain of apolipoprotein A-1 was used to create these new proteins, called membrane 
scaffold proteins (MSP). These consist of repeating units of α-helices, the number of 
which can be tailored in order to create different nanodiscs of differing sizes, 
approximately 9-13 nm in diameter.161 The two units of MSP wrap themselves around 
the hydrophobic core of the bilayer, protecting it from the bulk water and thus 
keeping a stable bilayer.162 
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Figure 63 - Structure of a Lipid Nanodisc formed by MSP. ©University of Illinois 
 
Nanodiscs are bilayer systems with no membrane curvature, and so can be a better 
model of membranes than experiments on monolayers and liposomes. These 
nanodiscs are most often used to study transmembrane proteins, which are imbedded 
in the nanodisc for individual study.163 However they are also useful for studying 
peripheral membrane binding proteins. Given their small size, we can expect only a 
few proteins to be able to bind to each face of the nanodisc, and thus it is possible to 
study individual molecules of hRSV-M binding. This was primarily attempted via 
dynamic light scanning and electron microscopy. 
 
The MSP protein used was MSP1E3D1, which is expected to generate approximately 
12.1 nm diameter bilayer discs and an approximately 9 nm thick lipid bilayer. To 
produce the nanodiscs, MSP1E3D1 was first produced by recombinant means. 
Briefly, a plasmid containing a His-tagged MSP1E3D1 construct was transformed 
into E.Coli BL21 and expression induced with IPTG. After 3 hours growth the cells 
were harvested and lysed to release the protein. The resulting supernatant was then 
purified by immobilised metal affinity chromatography (IMAC) using Ni-NTA, and 
stored in a buffer of 20 mM Tris pH 7.4, 0.1 M NaCl, 0.5 mM EDTA.  
 
For nanodisc formation, the lipids to be used (POPC/POPS 1:1 and POPS alone in the 
following experiments) are dried onto glass, and then rehydrated and solubilised using 
a solution of Sodium Cholate at twice the final lipid concentration (e.g. 50 mM Lipid : 
100 mM Sodium Cholate), with vigorous mixing, hating and sonication. The 
suspended lipids are then mixed with MSPE3D1 in a specific ratio, some examples of 
which are given below. It is crucial this stoichiometry is used, since even small 
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changes will result in aggregates and other sized entities. The mixture was then 
incubated for one hour at the specified temperature.162 
Lipid Optimal Ratio for 
MSP1E3D1 
Incubation 
temperature 
DPPC 170:1 37 °C 
DMPC 150:1 25 °C 
POPC / 
POPS 
130:1 4 °C 
Table 14 - Incubation conditions to form lipid Nanodiscs 
 
The resulting solution was then dialysed against a clean buffer in order to remove the 
Sodium Cholate. Doing so changes the lipid micelles into their final bilayer 
configuration surrounded by the matrix scaffold protein. The crude mixture of 
nanodiscs was finally purified by size exclusion chromatography on a HiLoad 16/600 
Superdex 200 PG column (GE Healthcare), coupled to an inline Dynamic light 
scattering (DLS) machine (Zetasizer µV, Malvern). The DLS was attached to identify 
nanodiscs of the correct diameter as they came off the column. 
 
 
Figure 64 - FPLC UV 280 nm trace for POPS MSP1E3D1 nanodiscs eluting from a Superose 12 
10/300 size exclusion column 
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2.13 Dynamic Light Scattering 
 
In order to observe the nanodiscs and any binding of hRSV-M to their surface, 
Dynamic Light Scattering (DLS) measurements were used. When light hits particles 
that are smaller than its wavelength, it can undergo Rayleigh scattering, and a DLS 
machine is designed to detect this scattered light. When carried out on particles in 
solution, the signal returned will not be constant, since the particles moving due to 
Brownian motion. This motion is dependent on the size of the particle, and this can be 
quantified by the Stokes-Einstein equation: 
t
B
h
D
Tk
D
πη3
=
 
Equation 25 
 
Where Dh is the hydrodynamic radius of the particle, kB is the Boltzmann constant, T 
is the temperature, η is the dynamic viscosity of the solution and Dt is the translational 
diffusion coefficient. In order to find Dt experimentally, the change in scattered light 
is measured over time, and an autocorrelation function is applied to it. This correlates 
the change in time between detected movements. This data can then be fit to an 
exponential decay of the form: 
)2exp( τΓ−=C  
Equation 26 
 
Where C is the autocorrelation function, τ is the decay time and Γ is defined by the 
equations: 
2qDt=Γ  
Equation 27 
And: 
)2/sin()/4( θλπnq =  
Equation 28 
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Where q is the scattering vector, n is the refractive index of the liquid, λ is the 
wavelength of the light, and θ is the scattering angle. This allows us to calculate Dt, 
and hence calculate the hydrodynamic radius from equation 25. 
 
The aim of these experiments was to see if the size of the nanodiscs is seen to change 
when hRSV-M is added, indicating that it has bound to the surface creating a larger 
particle. The following experiments were carried out in 10µl cuvettes, with an IR laser 
at 830 nm wavelength, and the scattering detector at 90° to the sample, and the sample 
in a 20 mM Tris-HCl, 200mM NaCl buffer. Fitting data is shown for hRSV-M as an 
example. 
 
 
Figure 65 - Fitting of the DLS autocorrelation function for hRSV-M 
 
Figure 66 - DLS data for hRSV-M, showing particle size distribution and calculated values 
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Sample Hydrodynamic 
particle size 
(diameter. nm) 
Peak width 
(diameter. nm) 
hRSV-M 7.84 1.34 
Table 15 - calculated parameters for hRSV-M from DLS 
 
The hydrodynamic diameter of hRSV-M appears to be quite large compared with the 
expected size from the protein crystal structure.39 This coupled with the quite wide 
peak width suggest that hRSV-M is conformationally flexible in solution, likely due 
to mobility of the C-terminus relative to the N-terminus. 
 
Figure 67 - Figure 51 - DLS data for POPS Nanodiscs, showing particle size distribution 
 
Sample Hydrodynamic 
particle size 
(diameter. nm) 
Peak width 
(diameter. nm) 
POPS 
Nanodiscs 
12.29 1.55 
Table 16 - calculated parameters for POPS MSPE3D1 nanodiscs from DLS 
 
The nanodiscs correspond to the expected size of 12.1 nm.162 The peak diameter of 
1.5 nm may suggest that the nanodiscs vary in size slightly, however this likely 
caused by their disc-shape (approx 9nm thick, 12.1nm wide). 
 
hRSV-M was then mixed with POPS nanodiscs in increasing ratios and the particle 
size recorded by DLS. The concentration of nanodiscs was 14 µM, and hRSV-M was 
added in increments of 2 molar equivalents, due to the assumption that it will bind on 
both faces of the nanodisc. An example of the size determination is shown for a 
hRSV-M to Nanodisc ratio of 10:1, and other ratios are summarised below. 
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Figure 68 - DLS data for hRSV-M added to POPC annodiscs at a 10:1 ratio. 
 
Ratio hRSV-M to 
nanodiscs 
Hydrodynamic 
particle size 
(diameter. nm) 
Peak width 
(diameter. nm) 
POPS Nanodiscs 
only 
12.29 1.55 
2 : 1 
13.01 1.87 
4 : 1 
13.51 2.02 
6 : 1 
14.93 2.43 
8 : 1 
14.92 2.23 
10 : 1 
15.32 2.53 
12 : 1 
15.40 1.91 
Table 17 - Particle size from DLS for varying rations of hRSV-M added to POPC nanodiscs 
 
The data shows that as increasing amounts of hRSV-M are added to the nanodiscs the 
hydrodynamic radius of the detected particles increases,  with a maximum being 
reached of 15.4 nm at ration of 12 to 1. This suggests that hRSV-M is binding the 
nanodiscs. Although the change in hydrodynamic diameter is not very great, 3.03 nm 
at maximum, this can be interpreted as hRSV-M forming a more condensed structure 
at the bilayer interface instead of the loose conformation seen in solution. This 
combined with the nanodisc’s natural disc shape mean that any change in the 
hydrodynamic distance perpendicular to the bilayer will be less visible by this 
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method. It is also possible that unbound hRSV-M and nanodiscs are bringing the 
average particle size down. 
 
2.14 Cryo-electron Microscopy 
 
Thanks are given to Dr David Bhella and group at the University of Glasgow Centre 
for Virus Research for carrying out the microscopy. 
 
While nanodiscs are too small to be seen by conventional light microscopy, they can 
be viewed by electron microscopy. Transmission electron microscopy is used since 
the wavelength of electrons is much smaller than visible light. This allows images of 
individual protein to be taken, or in this case of single nanodiscs. Usually, the samples 
are stained with heavy atoms in order to increase the contrast on a fixed substrate grid, 
however in this experiment Cryo-EM was used. This freezes the sample in liquid 
ethane and takes a thin section through the sample before being mounted in the 
electron beam. By keeping the temperature low, the sample can then survive inside 
the beam, and so the need for a mounting substrate or contrast agent is removed. Flash 
freezing the sample also means it is viewed in its native state, unlike techniques such 
as x-ray crystallography. The end goal of this experiment was to collect many images 
of nanodiscs with hRSV-M in order to build up an electron density map. This can then 
be fitted with the x-ray structure of hRSV-M to see how it has bound to the lipid 
bilayer.164 
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Figure 69 - Cryo EM images of POPC/POPS nanodiscs with hRSV-M (1:1 molar ratio). Left = 
Nanodisc from top, Right = Nanodisc on its side. 
 
  
Figure 70 - Cryo EM images of POPC/POPS nanodiscs highlighted in Red with possible hRSV-M 
highlighted in Yellow. Left = Nanodisc from top, Right = Nanodisc on its side. 
 
 
While nanodiscs could be easily seen in the images, the presence of hRSV-M was 
much more difficult to ascertain. Small particles could be seen attached to the lipid 
surface of some nanodiscs, however they were ill defined and many nanodiscs 
showed no features. They are approximately the size that would be expected for 
hRSV-M, being 6 nm in diameter when hRSV-M is expected to have a hydrodynamic 
diameter of 7.84 nm from DLS measurements and X-ray structure.39 The presence of 
these particles does fit quite well with DLS data previously shown for hRSV-M 
binding nanodiscs (section 2.13), with only a small overall increase in size observed. 
Unfortunately, it was determined that the nanodisc sample was too polydisperse for an 
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electron map to be created (possibly due to sample degradation in transport). This 
experiment therefore remains unresolved. 
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3 Results - Influenza A M1 
 
3.1 Purification and Protein Stability  
 
The Matrix protein (Inf-M1) from Influenza A was the other target of this project. The 
full length (252 a.a.) M1 gene was cloned using PCR of genomic DNA from 
Influenza A (Strain A/PR/8/34) with the following primers: 
 
Forward Primer: CACCCCGAATTCACCATGAGTCTTCTAACCGAGGT 
Reverse Primer: CGACGGCCGCTCGAGACTTGAACCGTTGCATC 
 
The forward and reverse primers contained restriction sites for EcoRI and XhoI 
respectively and these were used to clone the gene into the multiple cloning site of the 
vector pGEX-6P-1 (GE Healthcare). This vector was used because it provides a 
method of expressing the protein with a Glutathione-S-Transferase tag attached, 
which can then be used to purify the protein by its affinity to glutathione (Inf-M1-
GST). This vector also allows proteolytic cleavage of the GST tag, so allowing the 
native, un-tagged protein to be retrieved after purification. Cloning success was 
screened using colony PCR and DNA sequencing. 
 
Figure 71 - Colony PCR of pGEX-6P-1-M1 containing E.Coli colonies. Lane 1 = Generuler 1Kb 
ladder, Lanes 2-3 = Colonies of Transformed E.Coli 
 
Sequencing of the cloned plasmid showed that while the N-terminus was correct, 
attached to the GST fusion protein, at the C terminus there were 6 additional amino 
acids added to the sequence due to the cloning process used. However it was decided 
to continue with this clone. 
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GPLGSPEFTMSLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKNTDLEVLM
EWLKTRPILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDKAVKLY
RKLKREITFHGAKEISLSYSAGALASCMGLIYNRMGAVTTEVAFGLVCATCEQIADS
QHRSHRQMVTTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAAEAMEVASQARQMVQ
AMRTIGTHPSSSAGLKNDLLENLQAYQKRMGVQMQRFKSRAAAS  
Molecular weight: 29322.8 
Theoretical pI: 9.43 
Table 18 - Sequencing results of Inf-M1 expressed from pGEX-6P-1-InfM1. Underlined residues 
are not natural for Inf-M1, sequence only shown from after GST clevage site 
 
For expression of Inf-M1-GST, the plasmid was transformed into E.Coli Bl21 De3. 
Initial expressions using 1L culture flasks in LB media showed little expression, 
possibly due to a toxic effect of Inf-M1 on E.Coli. A scaled up protocol using a 2L 
bioreactor was therefore used to increase cell density.165 The transformed E.Coli were 
grown in 2L ZYM-5052 auto induction media166 at 37°C with a constant air supply 
for 5 hours, and then the temperature reduced to 20°C for a further 20 hours. The cells 
were then harvested, resuspended in a buffer of 50 mM sodium phosphate, 200 mM 
sodium chloride, pH7.4, and lysed by sonication. The resulting supernatant was 
purified by incubation with glutathione-sepharose beads (GE Healthcare), which were 
then washed thoroughly in clean buffer and one wash containing an additional 1M 
sodium chloride. Inf-M1-GST was then eluted from the resin using reduced 
glutathione. The reduced glutathione was removed by dialysis into clean buffer. The 
GST tag was then removed by treatment with PreScission® Protease overnight. The 
protease and the now free GST were removed by further incubation with Glutathione-
Sepharose beads, and the supernatant containing Inf-M1 removed. 
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Figure 72 - SDS-Page gel of first step in Inf-M1 purification. Lane 1 = Protein markers, Lane 2 = 
Supernatant from lysed E.Coli, Lanes 3-6, Washes of Glutathione-Sepharose 4B beads, Lane 7 =  
Elution of Inf-M1-GST from Glutathione Beads 
 
 
Figure 73 - SDS-Page gel of the cleavage of GST tag from Inf-M1. Lane 1= Protein markers, 
Lane 2 = Crude Inf-M1-GST, Lane 3 = Inf-M1 after cleavage and removal of GST 
 
Following this first step of purification, the samples were still determined to contain 
too many contaminants for use in experiments. Several different methods for a second 
step purification were tested; however the one that produced the best results was size-
exclusion chromatography. The protein was applied to a Superose 12 HR 10/30 (GE 
Healthcare) column and eluted into 50 mM sodium phosphate, 200 mM sodium 
chloride buffer. 0.5 ml fractions were collected, and screened by SDS-Page gel for the 
presence of Inf-M1. 
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Figure 74 - FPLC UV absorbance (280 nm)trace of crude Inf-M1 on Superose 12 HR 10/30 
column. Indicated peak = Inf-M1 
 
 
Figure 75 - SDS-Page gel showing fractions taken from size exclusion chromatography of Inf-M1.  
Lane = Protein Marker, Lanes 2-8 = FPLC fractions A8-A14, Lane 9 = fraction B5, Lane 10 = 
Inf-M1 before purification 
 
The identity of the purified protein was confirmed by mass spectrometry, giving 
exactly the expected mass of 29322 Da. 
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Figure 76 - Fourier Transform Mass Spectroscopy converted to neutral mass for a sample of Inf-
M1. Insert = Expansion of the peak at 29322 Da 
 
While the purification process gave a mostly pure protein (>98%), it can be seen in 
both the size exclusion chromatography and the mass spectrometry that smaller 
proteins can be seen at 17 kDa and smaller. It was further observed that these 
fragments became more prevalent over time as the protein was stored. The most likely 
reason for this is that the protein is degrading. While this behaviour had been 
observed with hRSV-M previously it occurred over a long time scale (>1 week), 
however with Inf-M1 this degradation can be observed very shortly after purification, 
as seen in figure 77. This fragmentation has been described previously, with the 
crystal structure for the N-terminus being produced after the fragmentation of the full 
length protein at amino acid residue 152.66 While this fragmentation was undesirable, 
it was decided that samples were still suitable if used on the day of purification, and 
re-purified for use on following days. 
 
James Freeth 2014 
 92 
  
Figure 77 - SDS-Page gels of Inf-M1. Left, Immediately after purification. Right, After 5 days 
storage at 4°C. 
 
3.2 Circular Dichroism and DLS 
 
Following purification, the structure of the protein was checked by circular dichroism 
measurements, using the same method as described in section 2.5. This was done to 
ensure the protein was correctly folded, and for comparison with literature data. The 
Continll algorithm again gave the best fit to the data. 
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Figure 78 - Circular Dichroism spectra for Inf-M1 
 
 Structural Feature (%) 
 α-Helix 
(regular) 
α-Helix 
(distorted) 
β-Sheet 
(regular) 
β-Sheet 
(distorted) 
Turn Irregular 
Inf-M1 20.0 17.7 8.3 6.3 20.9 26.8 
Table 19 - Secondary structural characteristics of Inf-M1 calculated Continll algorithm 
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The data collected shows M1 to be mainly alpha helix or disordered. This corresponds 
to data in the literature which suggest that the N-terminus is main alpha helical 
(46%)62 and the C-terminus is mainly disordered.167  
 
Dynamic light scattering data was also collected for Inf-M1. The data given below 
show that M1 has a slightly larger diameter than would be expected for a purely 
spherical protein of the same mass (approx 3.1 nm).168 This suggest that M1 is an 
elongated molecule, likely due to the mobility between the C and N-terminus. 
Alternatively it may indicate the Inf-M1 is forming a dimer in solution 
 
 
Figure 79 - Particle size distribution of Inf-M1 by DLS 
 
Sample Hydrodynamic particle 
size (diameter. nm) 
Peak width 
(diameter. Nm) 
Inf-M1 5.48 0.21 
Table 20 - Particle size calculated from DLS 
 
The small peak width indicates that the Inf-M1 molecules are likely in the same 
conformation in solution. 
 
3.3 Differential Scanning Fluorimetry 
 
In an attempt to find any conditions that may stop Inf-M1 from degrading as quickly, 
DSF analysis was carried out on it to identify binding partners. The same conditions 
and additives were used as for hRSV-M, as described in section 2.2. The protein was 
dialysed into 1mM Tris before usage. Only additives that caused a significant change 
in Tm are shown. 
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Table 21 - DSF data for Inf-M1 in 1mM Tris buffer pH 7.4 
 
 
Additive  Tm1 (°C) Tm2 (°C) 
None (PBS buffer) 53.8 - 
50mM Ethylenediamine dihydrochloride  50.5 63.6 
10mM Ethylenediaminetetraacetic acid 
disodium salt dehydrate 53.7 62.6 
50mM Ammonium Sulphate 53.9 65.9 
70mM Sodium Phosphate monobasic 
monohydrate + 130mM Potassium phosphate 
dibasic 54.0 68.3 
Table 22 - Tm values for Inf-M1 with additives used in DSF experiments 
 
The addition of the compounds shown in the collected data resulted in a second Tm 
being identified. As the samples were heated, they first underwent a denaturation 
event with a Tm of around 53°C which was largely unchanged by the additives. 
However, while this was a single event for the protein alone, with the above additives 
a second denaturation event can be seen with a much higher Tm. One interpretation of 
this is that these two events correspond to the separate C- and N-terminuses of the 
protein denaturing separately. Given the apparent structural order in the N-terminus, it 
seems likely that the change results from the C-terminus becoming more ordered.118 
The additives causing this effect being either metal chelators (Ethylenediamine, 
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EDTA) or ions that may precipitate metals (phosphate, sulphate) suggest that the 
increase in stability may be caused by the removal of a metal ion. Alternatively, it has 
been shown that some proteins contain phosphate/sulphate binding sites which can 
greatly increase their stability to denaturation though an increase in the solution 
surface tension of the protein.169-171 The exact cause of this change in stability cannot 
be determined from these experiments, but it was decided henceforth to use sodium 
phosphate based buffers for work on this protein. Unfortunately this change in buffer 
conditions made no difference to the protein degradation problems, indicating they 
have a different cause. 
 
3.4 Langmuir Isotherms and Brewster angle microscopy 
 
A plan was made to conduct Langmuir isotherm experiments in much the same way 
as ha been done for hRSV-M. The first experiment to be done was the effect of Inf-
M1 onto the air-water interface. However, when the protein was added it was found 
that the time taken for it to equilibrate was extremely long, far greater than would 
make it reasonable to perform isotherms on monolayers at equilibrium. The pressure 
could not even be seen to change until a large amount of protein had been added. 
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Figure 80 -  Time/Pressure plot for additions of Inf-M1 to a clean PBS subphase. At T=0, Inf-M1 
concentration was 1.49 nM, at arrow indicated more was added to make 25.26 nM total. 
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While this made characterisation of Inf-M1 impossible by this method, Brewster 
angle microscopy images could still be obtained to view any structures formed on the 
surface during this slow process. 
 
  
 
Figure 81 - BAM images of Inf-M1 on a PBS subphase. Top right Π = 0.1 mN m-1, top left Π = 1.1 
mN m-1, bottom Π = 4.6 mN m-1 
 
The images collected show that Inf-M1 does appear to form a condensed layer on the 
surface slowly over time, much like hRSV-M. 
 
Through the addition of a great excess of Inf-M1 to the subphase, it was possible to 
obtain a value for Πmax of 21.2 mN m
-1 for Inf-M1, achieved in excess of 122 nM. 
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Figure 82 - Pressure / Time plot for Inf-M1. The arrows indicate the addition of extra Inf-M1, 
giving a final concentration of 122 nM 
 
While most Langmuir trough experiments were ruled out, one further experiment was 
attempted. In order to see if Inf-M1 would have any effect on a monolayer over a long 
period of time, a monolayer of 15 µg DOPC/POPS (4:1) was formed, reaching Π = 
44.2 mN m-1. Once the pressure was stable, 5% (w/w) of Inf-M1 was added 
underneath the surface, giving a concentration of 13.62 nM. The pressure was then 
monitored over time, with BAM images being taken when possible. 
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Figure 83 - Pressure/ Time plot of 15ug DOPC/POPS (4:1) with 5% (w/w) Inf-M1 added to 
subphase (13.62 nM) 
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Figure 84 - Bam images of Pressure / Time plot of 15ug DOPC/POPS (4:1) with 5% (w/w) Inf-M1 
added to subphase (13.62 nM) . Top left = DOPC/POPS only, top right = 20000 seconds, bottom 
left = 30000 seconds, bottom right = 75000 seconds 
 
As can be seen in the data, very little change is seen in the pressure of the monolayer 
for the first 30000 seconds. However the BAM images show small domains forming 
on the surface. It appears the number of these domains becomes greater over time, 
until approx 45000 seconds, when the pressure begins to drop at a much faster rate. 
This may be interpreted as a loss of material from the surface. The pressure stabilised 
afterwards at 16.3 mN m-1. One possibility for this behaviour is that Inf-M1 has 
slowly been binding to the lipid monolayer, however it is only once it has reached a 
critical concentration at the monolayer that it is able to have an effect. It is then 
subducting lipids away from the surface, most likely in the form of micelles or 
liposomes surrounded by Inf-M1. This continues slowly until the remaining pressure 
makes the lipid too disperse for Inf-M1 to bind them and thus the process stops. 
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Unfortunately, time was not available to carry out follow up experiments to probe this 
behaviour. 
 
3.5 Giant Unilamellar Vesicles and confocal microscopy 
 
Inf-M1 was labelled with FITC in a 1:1 ratio using the same method as hRSV-M 
(section 2.10). It was then applied to GUVs consisting of DOPC/POPS (1:1) at a final 
concentration of 5 µM. This high proportion of phosphatidylserine was used due to 
preivous reports that Inf-M1 binds to membranes containing at least 50% 
phosphatidylserine.70, 83 The sample was then observed by confocal microscopy over 
one hour. Images are presented in false colour. 
 
 
Figure 85 - Confocal image of DOPC/POPS (1:1) GUVs with 5 µM Inf-M1-FITC at T = 0 
minutes. Top left = green channel, Top right = red channel, bottom = merged image 
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Figure 86 - Confocal image of DOPC/POPS (1:1) GUVs with 5 µM Inf-M1-FITC at T = 8 
minutes. Top left = green channel, Top right = red channel, bottom = merged image 
 
 
Figure 87 - Confocal image of DOPC/POPS (1:1) GUVs with 5 µM Inf-M1-FITC at T = 30 
minutes. Top left = green channel, Top right = red channel, bottom = merged image 
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Figure 88 - Confocal image of DOPC/POPS (1:1) GUVs with 5 µM Inf-M1-FITC at T = 50 
minutes. Top left = green channel, Top right = red channel, bottom = merged image 
 
As the data shows, initially no binding of Inf-M1-FITC to GUVs can be seen. 
However after 8 mins it was observed that Inf-M1-FITC was binding to the surface of 
GUVs, with some denser patches of Inf-M1-FITC forming, as seen by the higher 
fluorescence. By 30 minutes into the experiment, the Inf-M1-FITC appears to have 
budded away from the surface of the GUVs and forming new small vesicles with 
some of the material. By 50 minutes there were few remaining large GUVs, with most 
now having budded into small vesicles, although these still remain associated with 
each other. 
 
This behaviour of budding vesicles is not unique to Inf-M1, it has been described in 
Newcastle disease virus previously, however the budding was internal to the GUV, 
not externally as seen in the data presented here.118 The budding may be caused by 
crowding of the protein at the surface of the GUVs, where lateral pressure exerted by 
proteins being in close proximity on the surface cause a curvature and eventual 
vesicle budding from a bilayer.172 However we cannot identify from this experiment if 
the protein remains on the outer or inner face of the new vesicles. 
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4 Discussion and Conclusions 
 
4.1 hRSV-M as a calcium binding protein 
 
While this project began focused on the lipid interactions of hRSV-M, the 
experiments performed have led to alternative discoveries. Since the x-ray crystal 
structure of hRSV-M has been previously determined, and previous mass 
spectrometry experiments had failed to find any metals bound to hRSV-M, it was not 
expected that further experiments would show the presence of metals.39, 47 However 
this has proven to not be the case, with the data presented here showing that when the 
protein is incubated with calcium, and kept out of conditions that precipitate or 
chelate calcium ions, that calcium ions can be found bound. Two sites were identified, 
one with strong binding and another with very weak. Given the ICPMS data showed 
only one calcium bound per protein, it is likely that this second site is non-function 
with respect to in-vivo activities. 
 
The presence of metals in viral proteins is well known, however to date they have 
mainly been localised to proteins involving transcription and interactions with RNA, 
for example Ebola virus VP30 binding zinc to activate transcription and HIV-1 
RNase-H using magnesium as a cofactor.173, 174 A search of the literature shows that 
zinc is by far the most common metal ion found to bind viral proteins, and there was 
only one instance of a viral matrix protein binding metal, the Zinc binding behaviour 
of Influenza A M1.175 Calcium binding to viral structural proteins was unknown until 
very recently, although it has been known that viruses do have large effects on 
calcium levels within cells and utilise cellular calcium binding proteins.126 
 
However, following the completion of this work on hRSV-M’s calcium binding 
characteristics, a paper by Leyrat et al. was published showing the crystal structure 
and calcium binding sites of Human Metapneumovirus M (HMVP-M).176 The 
structure shows very high homology with that of hRSV-M, and a calcium ion can be 
found bound to a site within the N-terminus. The binding residues are Glu24, Asp26, 
Leu/Asp28 (in HMPV-M / RSV-M respectively) and Lys101. 
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Figure 89 - X-ray crystal structures of hRSV-M (Top, PDB ID = 2VQP) and HMPV-M (Bottom, 
PDB ID = 4LP7). Blue = N-terminus, Red = C-terminus, Green = Residues of high affinity Ca2+ 
binding site 
 
 
Figure 90 - Close view of residues Glu24, Asp26, Asp28 and Lys101, forming potential calcium 
binding site 
 
As can be seen from the X-ray structures, the high affinity calcium binding site of 
HMPV-M is highly conserved in hRSV-M, making it very likely that this site is the 
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higher affinity site observed in our data. However, the residues in hRSV-M are in an 
open conformation, with the residues turned away from the potential calcium site. 
This is likely also responsible for the large differences in Kd calculated for this site in 
hRSV-M (Kd = 1.95µM) and HMPV-M (Kd = 2.0nM). I t appears that the slight 
structural changes in hRSV-M are enough to lower the affinity of this binding site.176 
In the x-ray crystal strucuture of hRSV-M, these residues around the binding site have 
slightly less well defined electron density, with residues 99 and 100 not being directly 
assigned in the structure, further showing that this binding pocket may be flexible. 
 
They also identified a second potential calcium binding site with a much higher Kd 
(158 µM), formed of residues Val94, Asp97, Glu98 and Gln231. These residues are 
again conserved in hRSV-M, suggesting this is also the low affinity site in this 
protein. Since ICPMS showed this site to not be occupied once the protein was 
removed from a calcium containing solution, this site may be involved in increasing 
stability of the protein in the extracellular fluid where the free calcium concentration 
is much higher. 
 
The role of calcium in hRSV-M has yet to be established. Calcium levels within a cell 
are altered by many viruses, with RSV replication and syncitium formation shown to 
be inhibited by low cellular levels of calcium, and the degree of conservation of these 
residues suggests that they are important for the virus.177 The calcium content of a cell  
Leyrat et al. suggest that since the Ca2+ binding site is on the convex face of M it is in 
contact with the nucleocapsid proteins, and so Ca2+ binding may be a method of 
controlling virus assembly and budding. 
 
4.2 hRSV-M interacting with lipids and membranes 
 
This work has helped further our understanding of hRSV-M interacting with lipids. 
Our group has previously reported on the interactions of hRSV-M with 
DOPC/Sphingomyelin/Cholesterol monolayer mixtures, with the opinion that hRSV-
M was partitioning into the Ld phases of this mixture, while binding extrinsically to 
the Lo phases. Experiments using single component monolayers of cholesterol and 
sphingomyelin showed that these lipids do not show any specific interaction with 
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hRSV-M. However when these lipids were combined the behaviour of the protein 
changed but still showed insertion into the monolayer. This suggest that the 
previously observed behaviour is unique to the ternary mixture of these lipids. One 
possibility is that the protein requires a specific line tension in order for interaction 
with the surface to occur, as line tension has been shown to be important in viral 
budding.178, 179 This is supported by the experiments with DOPC/SM/Chol GUVs 
which again showed binding of small amount of hRSV-M to their surface. 
 
This work has also shown that hRSV-M has a great affinity for binding the negatively 
charged phosphatidylserine lipids. The binding of hRSV-M to a monolayer of 
DOPC/DPPS can be seen by BAM to induce the formation of small domains, 
presumably clusters of protein that have organised the lipids into DPPS rich domains, 
and overall stabilising the monolayer. The experiments with GUVs however showed 
the most convincing results with phosphatidylserine. It could be seen the hRSV-M 
was unable to cross a membrane bilayer, but instead could be found binding to 
patches on the outside of phosphatidylserine containing GUVs. The domains were 
smaller on those GUVs with a lower phosphatidylserine ratio, likely due to hRSV-M 
clustering the available DPPS into highly enriched domains, but the available DPPS 
being depleted before these domains could grow larger. This interaction of HRSV-M 
with a negatively charged membrane has also been shown in other viral matrix 
proteins, such as HIV-1-Gag, Influenza a M1 and Ebola VP40.83, 90, 180 The strong 
interaction with negatively charged lipids is likely due to the 600 Å2 positively 
charged face of the protein found in the x-ray crystal structure.39 
 
When the Lo domains of a sphingomyelin/cholesterol mixture and phosphatidylserine 
were combined, the effect of hRSV-M on the GUV changed quite dramatically. While 
at first hRSV-M bound all over the surface of the GUVs, after a short time small spots 
of high hRSV-M density were observed. It is possible that a combination hRSV-M 
clustering phosphatidylserine together and the increased membrane pressure from the 
Lo lipid components crated conditions for hRSV-M to oligomerise and form the 
beginnings of a virus-like particle. 
 
Unfortunately the work started on hRSV-M with lipid nanodiscs was not able to be 
fully completed due to time constrains. However the initial experiments showing 
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potential hRSV-M binding to POPS nanodisc does suggest that these may be a useful 
tool in the future for studying peripheral membrane binding proteins and determining 
their membrane bound structure. 
 
4.3 Influenza A M1 
 
While work on Influenza A M1 was not advanced very far due to time constraints, the 
experiments so far have proved a useful starting point for further work to study this 
protein. A robust method has been developed for the expression and purification of 
Inf-M1, and the limits of its stability have been found. Domain formation of 
phosphatidylserine containing monolayers was observed, in a similar manner to that 
described for hRSV-M, except over a much longer time span. The longer time span 
involved in Inf-M1 membrane interactions suggests that there is another mechanism 
involved in targeting it to membranes that has yet to be identified. 
 
Inf-M1 binding to GUVs containing a high proportion of phosphatidylserine showed 
that the protein is able to induce vesicle budding over time. A likely interpretation of 
this is that Inf-M1 binds to the surface and induces a change in membrane curvature. 
After a critical amount of protein has bound to a small portion of the membrane the 
pressure exerted by the protein is enough to cause the budding. This mechanism has 
been identified as an intrinsic property in several other proteins.179, 181 Similar 
behaviour has been observed in the related Newcastle disease virus, where binding of 
the protein caused vesicle formation, however this did not require phosphatidylserine 
and the vesicles budded inward of the GUV.97, 182 The observed affinity of Inf-M1 to a 
negatively charged membrane corresponds to previously published data.83  
 
4.4 Future Work 
 
4.4.1 hRSV-M 
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While the investigation of calcium interacting with hRSV-M was started, there are 
further experiments that may be conducted in the future to expand our knowledge. A 
first step, given the results of Leyrat et al. is to attempt to crystallise hRSV-M with 
calcium present. If a structure can be found with one or both calcium binding sites 
occupied it may help to explain the differences in calcium Kd seen between HMPV-M 
and hRSV-M, and the changes in protein stability observed. This experiment was 
attempted and crystals were formed, however they did not diffract. If crystals are 
unable to be formed, then small angle x-ray scattering (SAXS) to give some structural 
information of any possible changes upon calcium binding. 
 
While a calcium binding constant was collected during this work, it would be 
advisable to confirm the values through other experiments. A technique such as 
isothermal titration calorimetry could be used for this, while also giving extra 
parameters for the interaction. The main downside of this is that the weak binding of 
the second site may make it difficult to analyse. Another alternative technique would 
be to use a fluorescent calcium binding molecule and conduct a competitive binding 
assay. 
 
While the lipid binding characteristics of hRSV-M have been clarified further, there 
are still more interesting possibilities to look into. While the negatively charged 
phosphatidylserines have been looked at in this work, it would be useful to study 
other negatively charged lipids found in the membrane. Particularly, the 
phosphatidylinositols can be highly negatively charged due to multiple phosphate 
groups, and are often found in viral envelopes.141 Phosphatidylglycerols may also be a 
good candidate, since they are found predominately in lung surfactant, which hRSV-
M is likely to come into contact with during infection cycles.183 
 
GUV experiments may also be continued. It may be useful to study mixtures of lipids 
where phosphatidylserine is localised to either Lo or Ld domains, to see if the 
clustering effect of hRSV-M on these lipids remains. GUVs can also be formed out of 
lipids extracted from cells, and using these would reveal the natural behaviour of 
hRSV-M on cell membranes.155 The binding kinetics could also be studied by using a 
micro-injector to inject small amounts of hRSV-M close to the surface of a GUV and 
monitor its effects over time. Domain formation could also be visualised by this 
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method. GUVs could also be used for patch-clamp experiments, monitoring the 
electrical admittance over time as hRSV-M binds to the surface. 
 
 
 
To study the conformation of hRSV-M binding to lipids, Fluorescence resonance 
energy transfer (FRET) could be used. This could be done in two different ways to 
give different information. By a modification of the existing GUV method using two 
suitable fluorophores, one on the protein and one in the membrane, and a confocal 
microscope able to do fluorescence lifetime imaging (FLIM). Measuring the distance 
between the fluorophores would tell us at what orientation the protein has bound to 
the membrane. Alternatively, by labelling the protein with two fluorophores, one at 
the N-terminus and one at the C-terminus, it may be possible to determine the 
orientation of the two domains relative to each other upon lipid binding. 
 
The orientation of hRSV-M could also be determined by neutron reflectivity 
experiments. An attempt was made to do this at ILL, Grenoble, however binding 
could not be seen. With the details learned in the work about the binding of hRSV-M, 
it may be possible to collect better data now. 
 
4.4.2 Infuenza-A-M1 
 
Many of the experiments carried out on hRSV-M can be extended to Inf-M1. A major 
goal in research on Inf-M1 would be the crystallisation and 3D structural 
determination of the intact protein. While the N-terminus has been determined, the C-
terminus and linker region have not been crystallised. Conditions were tested for 
crystallisation, however no crystals formed. SAXS and Neutron reflectivity may also 
prove useful in determining the full structure of Inf-M1. 
 
One planned experiment that unfortunately could not be completed was to apply Inf-
M1 to lipid nanodiscs in the same matter as hRSV-M. The reasoning for this was that 
the rapid degradation of the protein may make crystallisation of the intact protein 
impossible, and so by instead binding Inf-M1 to nanodiscs and collecting the electron 
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density from Cryo-EM images it may be possible to build up a model of Inf-M1. It 
may also give valuable information on its lipid binding surface and possible oligomers 
formed at the lipid surface. FRET experiments similar to those described above may 
also be useful. 
 
Since Langmuir isotherms may not be a possible method for examining Inf-M1 lipid 
binding, other methods may be examined. Using ITC with Inf-M1 and liposomes 
would allow binding parameters to be calculated. Imaging of Inf-M1 bound to a 
membrane could also provide valuable information, and could be achieved by atomic 
force microscopy of a prepared bilayer from a Langmuir-Blodgett deposition. 
 
The ability of Inf-M1 to bud small vesicles/liposomes away from giant vesicles 
suggests that it may be a good candidate for patch clamp technique. This technique 
has already been used for similar behaviour seen in Newcastle disease virus.182 By 
taking a patch of a GUV membrane and applying Inf-M1 to it, the electrical 
admittance would change as the composition of the membrane changes as lipids are 
removed. 
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6 Materials and Methods 
 
6.1 General 
 
All chemicals were used as received unless stated otherwise. All solvents used were 
reagent grade from Fischer Scientific, (Thermo Fisher Scientific, Loughborough, 
UK). Water was purified using a Milli-Q system (Millipore, Billerica, MA, USA) to a 
resistivity of 18.2 MΩ. 
 
Phosphate buffered saline (PBS) pH 7.4 was purchased from Invitrogen, Paisley, UK, 
at 10x concentration (105 mM KH2PO4, 305 mM Na2HPO4, 1.54 M NaCl) and diluted 
to a working stock of 1x, the pH readjusted to 7.4 with HCl. All buffer components 
were purchased from Sigma Aldrich (Sigma-Aldrich Ltd, Dorset, UK). 
 
Factor Xa was purchased from Novagen (Novagen, Merck Chemicals Ltd, 
Nottingham, UK). PreScission® Protease and Glutathione-Sepharose B beads was 
purchased from GE Healthcare (GE Healthcare Life Sciences, Buckinghamshire, 
UK). Protein Markers, Restriction Enzymes and Pfu polymerase were purchased from 
NEB (New England Biolabs (UK) Ltd, Hertfordshire, UK). Ni-NTA beads were 
purchased from Quiagen (Quiagen, Manchester, UK) 
 
All lipids were obtains as solids. DPPC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine) was purchased from Bachem AG, Bubendorf, Switzerland. DOPC 
(1,2-dioleoyl-sn-glycero-3-phosphocholine), DPPS (1,2-dipalmitoyl-sn-glycero-3-
phospho-L-serine) and cholesterol were Sigma brand (Sigma-Aldrich Ltd, Dorset, 
UK). POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine) and Egg 
Sphingomyelin were purchased from Avanti Polar Lipids (Avanti Polar Lipids, 
Alabama, UK). Lipids were dissolved in chloroform or 3:1 chloroform: methanol and 
stored at -20°C. 
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6.2 Expression and Purification of hRSV-M 
 
A pET16b vector containing the ORF of M protein was transformed into CaCl2 
competent E. coli BL21(DE3)pLysS by heat shock transformation. After culturing of 
a small overnight starter culture, the bacteria were grown in ZYM-5052 auto-inducing 
media with Ampicillin (100 µg/mL) and Chloramphenicol (50 µg/mL) at 37oC for 8 
hours, then 20oC for 48 hours until no change in the OD600nm was observed. The 
cells were harvested by centrifugation of the culture at 5000 x g for 15 minutes. 
 
For protein extraction, the E.Coli pellet was resuspended in 1/20th the culture volume 
of Tris based buffer (20 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2 pH 7.4) with 
Lysozyme (1µg/mL) and chilled in ice for 30 minutes. DNase 1 (1 µg/mL) and RNase 
A (1 µg/mL) were added and the cells lysed by sonication. CHAPS (8 mM) was 
added and the lysate was centrifuged at 50,000 x g for 30 minutes; removing the 
supernatant. Imidazole (0.05 M final concentration) and Ni-NTA agarose beads (50% 
suspension, 0.75 mL per L of culture) were added and the mixture placed on a 
carousel for 30 minutes at 4oC. The mixture was centrifuged at 100 x g for 2 minutes 
and the supernatant discarded. The beads were resuspended in 50 ml Tris buffer with 
Imidazole (0.05 M) and loaded onto a column. The liquid was allowed to flow 
through under gravity, before the beads were washed with 50 ml Tris buffer with 
Imidazole (0.1 M). The protein was eluted from the Ni-NTA beads using successive 
washes of 10 ml Tris buffer with increasing concentrations of  imidazole (0.2 – 0.5 
M) and the fractions analyzed by SDS-PAGE. Fractions containing the protein were 
dialysed into Tris buffer and stored at 4oC. The His-tag was removed using Factor Xa 
enzyme, as per the manufacturer’s instructions (Novagen, Merck Chemicals Ltd, 
Nottingham, UK). 
 
6.3 Cloning, Expression and Purification of Inf-M1 
 
6.3.1 Cloning 
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Template plasmid containing the M1 gene was supplied by collaborators and was 
amplified using the Pfu DNA polymerase according to manufacturers instructions and 
the primers described below, containing EcoRI and XhoI restriction sites, followed by 
purification using a QIAquick PCR purification kit (Quiagen). The target plasmid 
pGEX-6p-1, and the amplified gene were restricted using EcoRI and XhoI according 
to the manufacturer’s instructions and purified using a QIAquick gel extraction kit 
(Quiagen). The restricted plasmid and gene were ligated overnight with T4 
polymerase and transformed into E.Coli XL1-Blue and the grown overnight on 
ampicillin containing LB-Agar plates. Colonies were screen by colony PCR and 
positive colonies were picked to be cultured and used to harvest more of the cloned 
plasmid. 
Inf-M1 primers: 
Forward Primer: CACCCCGAATTCACCATGAGTCTTCTAACCGAGGT 
Reverse Primer: CGACGGCCGCTCGAGACTTGAACCGTTGCATC 
 
6.3.2 Expression and Purification 
 
pGEX-6P-1-Inf-M1 was transformed into CaCl2 competent E. coli BL21(DE3) by 
heat shock transformation. An overnight starter culture of 10ml LB medium with 
Ampicillin (100 µg/mL) was inoculated with the transformed E.Coli. A 2 Litre 
Bioreactor (Sartorius, Goettingen, Germany) was set up, containing 2L ZYM-5052 
autoinduction media with 100uL Antifoam A (Sigma-Aldrich), Ampicillin (100 
µg/mL) and Chloramphenicol (50 µg/mL). This was inoculated with 10ml of the 
overnight starter culture. The bioreactor was kept agitated by a mixing motor @ 
1000rpm, and had a constant compressed air supply piped into the bottom of the 
reactor. The culture was heated to 37°C using a heating jacket for 5 hours, and then 
the temperature reduced to 20°C. The OD 600 nm was monitored throughout the 
experiment and when the value stopped increasing (usually 24 hrs), the cells were 
harvested by centrifugation of the culture at 5000 x g for 15 minutes. 
 
For protein extraction, the E.Coli pellet was resuspended in 1/20th the culture volume 
of Phosphate buffer (50 mM NaH2PO4, 0.2 M NaCl, pH 7.4 pH 7.4) with Lysozyme 
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(1µg/mL) and chilled in ice for 30 minutes. DNase 1 (1 µg/mL) and RNase A (1 
µg/mL) were added and the cells lysed by sonication. CHAPS (8 mM) was added and 
the lysate was centrifuged at 50,000 x g for 30 minutes; removing the supernatant. 
Glutathione-Sepharose B beads (50% suspension, 1 mL per L of culture) were added 
and the mixture placed on a carousel for 1 hour at 4oC. The mixture was centrifuged 
at 100 x g for 2 minutes and the supernatant discarded. The beads were resuspended 
in 50 ml Phosphate buffer and loaded onto a column. The liquid was allowed to flow 
through under gravity, before the beads were washed with 50 ml Phosphate buffer. 
The beads were then removed and treated with 50mM reduced glutathione. The 
supernatant was dialysed into Phosphate buffer with a minimum 20x volume, and 
then PreScission® Protease added (0.5 µl per ml) and incubated overnight at 4°C. 
Afterwards, Glutathione-Sepharose B beads (1ml) were added and the mixture placed 
on a carousel for 1 hour at 4oC. The supernatant was removed and applied to a 
Superose 12 HR 10/30 (GE Healthcare) column equilibrated with Phosphate buffer. 
The column was ran at a rate of 0.5 ml per minute and fractions of 0.5 ml collected. 
Fractions were analyzed by SDS-PAGE. Fractions containing the protein were 
dialysed into PBS and stored at 4oC. 
 
6.4 Protein Characterisation 
 
6.4.1 SDS-Page Gel electrophoresis 
 
SDS-Page gels were made using the Biorad Mini-Protean Equipment. The gels used 
were 12.5 % acrylamide gels, with the following compositions for 1 gel: 
12.5 % Resolving Gel: 
H2O – 1.75 ml 
Resolving buffer – 1.25 ml 
30 % Acrylamide – 2 ml 
10 % Ammonium Persulphate – 25 µl 
TEMED – 5 µl 
 
4 % Stacking Gel: 
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H2O – 1.15 ml 
Stacking buffer – 0.5 ml 
30 % Acrylamide – 0.335 ml 
10 % Ammonium Persulphate – 15 µl 
TEMED – 2.5 µl 
 
SDS Running buffer: 
Glycine – 196 mM 
3.6 % Sodium Dodecyl Sulphate 
Tris-HCl – 50 mM 
pH 8.3 using HCl 
 
The gel was assembled as described in the manufacturer’s instructions. The proteins 
samples to be run on the gel were mixed 1:1 with SDS loading buffer (50 mM Tris-
HCl pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, 0.02 % 
bromophenol blue) and heated at 95oC for 15 mins. The gel was placed into a tank 
filled with running buffer and 10-20 µl of the sample was then loaded into the gel. 
The electrophoresis power pack was set to 200 V for 40 mins and the gel ran. 
The gel was then stained with 0.05 % coomassie blue stain and destained with 10 % 
methanol / 10 % acetic acid solution, to show the protein as blue bands on the gel. 
Along with the samples to be analysed, a maker was also always added to estimate the 
size of the protein’s on the gel. 
 
6.4.2 Protein Concentration Measurement 
 
A quartz cuvette filled with 1 ml of 6M Guanidinium Hydrochloride was used as a 
blank in a UV spectrometer at 280 nm. Sequentially, 5 µl, 10 µl, 15 µl and 20 µl of 
protein solution were added to the cuvette and the absorbance recorded. Absorbance 
values were corrected for the change in volume (A(Corr)). 
0
0 )()(
V
VV
ACorrA
+
=  
Equation 29 
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Using a variation of the Beer-Lambert law: 
0
..
)(
V
Vx
CorrA
ε
=  
 
Where ε is the absorption coefficient of the protein (M-1cm-1) and x is the protein 
concentration (M). A plot of A(corr) against V gave a straight line with a gradient 
(εx)/V0 ad so x  can be calculated.  
 
Values for ε were calculated based on their amino acid composition where: 
 
)]()([)]()([)]()([)( CystineCystinenTrpTrpnTyrTyrnprotein εεεε ×+×+×=  
 
Using ε(Tyr) = 1285, ε(Trp) = 5685 and ε(Cystine) = 125 M-1cm-1 
From this, values of ε = 24220 M-1cm-1 were used for hRSV-M, and ε = 13075 M-1cm-
1 for Inf-M1. 
 
6.4.3 Mass Spectrometry 
 
Samples were processed by the Mass Spectrometry unit at Durham University. 
For routine mass spectrometry, samples were analysed by MALDI-TOF mass 
spectrometry with a sinapinic matrix on a Bruker Daltonics Autoflex TOF/TOF. 
For MS/MS experiments, samples were run on a LTQ FT (ThermoFinnigan) coupled 
to a liquid chromatography system. 
 
6.4.4 Differential Scanning Fluorimetry 
 
A 96 well plate was filled with 2 µl of solution from a Hampton Solubility and 
Stability Screen (see Appendix) using a Innovadyne pipetting robot. Protein of 
concentration 0.1-0.5 mg/ml was mixed with SYPRO orange 5000X (Sigma-Aldrich) 
to a final dye concentration of 10X and 18µl added to each well. The plate was sealed 
and centrifuged at 1000 rpm for 2 minutes. The plate was then placed into a Applied 
Biosystems 7500 FAST real time PCR system. The samples were then heated for 24 
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to 95°C at a rate of 1°C per minute and the fluorescence data collected using filter set 
3. 
 
6.4.5 ICPMS 
 
hRSV-M was incubated with 5mM CaCl2 for one hour, followed by salt exchange 
using a PD-10 desalting column (GE Healthcare) equilibrated in 10 mM MOPS, pH 
7.4, with the effluent collected in 0.5ml fractions. The protein concentration of each 
fraction was determined before continuing. 3 ml samples were prepared consisting of 
2.4 ml Nitric acid, 300 µl H2O and 300 µl of protein fraction. Alongside this, 
standards of CaCl2 were prepared with the same component consistency as the 
protein samples (40 ml Nitric acid, 5 ml buffer, 5 ml water) at concentrations of 10 
ppm, 1 ppm, 100 ppb and 10 ppb. Samples and standard were then loaded into an 
Inductively coupled plasma-mass spectrometer (ICP-MS) (Thermo X-series) with 
Cetac ASX510 autosampler. The spectrometer was set to measure calcium at 40.078 
Da and the samples processed. 
 
6.4.6 Microscale Thermophoresis 
 
hRSV-M was labelled with the dye NT-647 (L001 Monolith™ NT.115 Protein 
Labelling Kit RED-NHS) in a 1:1 ratio according to the manufacturers instructions. 
The protein was then buffer exchanged into MST optimised buffer (50 mM Tris-HCl, 
150 mM NaCl, 0,05 % Tween-20). A set of serial dilutions of CaCl2 in MST 
optimised buffer were prepared (10 nM – 10 mM final concentration) and 20 µM final 
concentration of hRSV-M-NT-647 added to each. 4 µl of each sample was then 
loaded into capillary tubes and placed into the Monolith NT.115 Instrument 
(NanoTemper Technologies GmbH, Munchen, Germany). The experiment was then 
run using preset settings and the resulting data analysed on the software’s bespoke 
tools. 
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6.4.7 Circular Dichroism Spectroscopy 
 
Protein samples were dialysed into 1mM Tris pH7.4 or 5mM phosphate buffer pH 7.4 
with any additives before use. A sample of the same buffer was used as a blank. 
Samples were placed into a 0.2 cm pathlength quartz cuvette and loaded into a Jasco 
J-810 Spectropolarimeter. The temperature was held at 25°C using a peltier controlled 
water jacket. Spectra were collected between 260 and 180 nm at a rate of 10 nm/min, 
a pitch of 0.5 nm, a bandwidth of 1 nm and a response time of 2 s. 8 spectra were 
collected for each sample and averaged for analysis. Protein samples were diluted 
down until the detector was not saturated within the collection range. The blank buffer 
spectra were subtracted from the collected protein spectra and then subjected to 
analysis. Data points for which the HT voltage was over 600 were discarded as 
unreliable. The package CDPro was used for analysis, containing the secondary 
structure algorithms SELCON3, CDSSTR and CONTIN/LL. All viable reference 
protein sets were used, but dataset 10 resulted in the best fittings for all proteins 
studied. 
 
6.5 Membrane Interactions 
 
6.5.1 Langmuir Isotherms 
 
Experiments were carried out on a 150 x 70 mm Langmuir trough (102 M, Nima 
Technology Ltd, Coventry, UK) with two moveable Delrin barriers. Before and after 
each experiment the trough was thoroughly cleaned using Kimwipes and either 
isopropyl alcohol or chloroform / methanol 8:2. With the barriers open, the trough 
was filled with PBS pH 7.4, the Wilhelmy plate attached to the pressure sensor and 
the surface cleaned with an aspirator. The barriers were then closed and the pressure 
monitored. The surface was cleaned further until the change in pressure was less than 
0.2 mN m-1 in total. The required mass of lipids dissolved in chloroform (+ methanol 
if required) were deposited on the surface using a glass micro-syringe and allowed 15 
minutes to equilibrate. For pressure/area experiments with protein (with or without 
lipids), the protein was added first to the surface with a micropipette followed 
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immediately by the lipid if required and given 15 minutes to equilibrate. Isotherms 
were collected by closing the barriers at a rate of 8 cm2 per minute and the change in 
pressure recorded every 0.2 seconds. For protein only experiments at a fixed area, the 
change in pressure was recorded without any equilibration time, starting from when 
the protein was first added. For protein being added to a fixed area lipid monolayer, 
the lipids were deposited on the surface first, followed by injection of the protein just 
underneath the surface of the subphase and data immediately recorded. 
 
6.5.2 Brewster Angle Microscopy 
 
The equipment used in this experiment is shown in figure 43. The Langmuir trough 
was filled with PBS and the surface cleaned by aspiration. Light from a p-polarised 
633 nm helium-neon laser (CVI Melles-Griot, Leicester, UK) was passed through a 
Glan-Taylor Polariser and adjusted with mirrors so it made an incident angle of 53° to 
the subphase surface. The CCD video camera (OPtem Zoom 70, Qioptik Imaging 
Solutions, Newport, NY, USA) was also set to this angle to capture reflected light. 
The angle of the incident beam was adjusted slightly until no reflection could be seen 
from the clean subphase surface. Samples on the subphase surface were then set up in 
the same manner as Langmuir isotherm experiments. Images were recorded and saved 
manually during the experiment. 
 
Fluorescent labelling of protein 
 
Either FITC (10 mM in DMSO) or NBD-Cl (10mM in DMF) was added in a 1:1 
molar ratio to protein in its storage buffer and incubated at room temperature for one 
hour. The protein was then applied to a PD-10 desalting column equilibrated in 
storage buffer, mand eluted with further buffer. The eluted protein was analysed by 
UV-Vis spectroscopy at 280 nm (protein) and 494 nm for FITC (ε = 68000 M-1 cm-1) 
or 480 nm for NBD (ε = 25000 M-1 cm-1) to determine the extent of labelling. 
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6.5.3 Giant Unilamellar Vesicle preparation 
 
10 µg of lipids in chloroform were dried onto the conductive sides of two ITO coated 
slides (30-60 Ω/sq, Sigma-Aldrich) for at least 1 hour in a desiccator. A nitrile-o-ring 
was lightly covered in vacuum grease and the slides with dry lipids pointing inwards 
were then assembled separated by the o-ring with 170µl of sucrose solution (5 mM 
Phosphate buffer pH 7.4, 300 mM Sucrose) filling the well. The slides were brought 
into in contact with copper strips connected to a programmable function generator. 
The whole assembly was then placed inside a thermostatically controlled oven. The 
entire apparatus was pre-heated to 70°c and maintained for the electroformation steps. 
The function generator was then used to pass a current gradient through the cell with 
the following steps: 
 
Step Time 
(hr:min) 
Start 
Voltage (V) 
End 
Voltage (V) 
Frequency 
(Hz) 
Wave form 
1 0:10 0.1 1.2 10 Sine 
2 3:00 1.2 1.2 10 Sine 
3 0:20 1.2 1.2 5 Square 
Table 23 - Function generator settings for GUV formation 
 
Following completion of the electroformation steps, the apparatus was slowly cooled 
from 70°C to 20°C over 3 hours. The GUVs were then removed and ready for use. 
 
6.5.4 Confocal Microscopy 
 
A Teflon coated well was made and glued on top of a glass cover slip. This was then 
treated with 1mg/ml BSA for 5 hours to passivate the surface, before being rinsed 
with 5 mM Phosphate buffer pH 7.4. For experiments using GUVs only, the well was 
filled with 1 ml of 5 mM Phosphate buffer, ~300 mM Glucose which had been 
adjusted to the same osmotic strength as the sucrose solution by adding more 
phosphate buffer. Osmotic strength was measured using a Osmomat® 030 (Gonotec, 
Berlin, Germany). The 5 µl of GUVs were then added to the solution, where they sank 
to the bottom of the well. For experiments where protein was to be added, the osmotic 
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strength of the fluorescent protein was measured and both the glucose and sucrose 
solutions were matched to this osmotic strength. The protein was then added to the 
well after the GUVs to a final concentration of 5 µM. 
 
The samples were observed using either a Biorad Microradience 2000 (Biorad, 
Hertfordshire, UK) or a Zeiss 510 Meta (Carl Zeiss, Cambridge, UK). Rh-PE was 
excited using a 543.365 nm GreenNe Laser and fluorescence detected with a 
photomultiplier tube with an E570nm Longpass filter. NBD-PE and hRSV-M-FITC 
were excited using a 488.0 nm Argon Laser and fluorescence detected with a 
photomultiplier tube with a HQ530/60 nm Bandpass filter. Images were processed 
using LSM Image browser, given scale bars and false colour. 
 
6.5.5 MSPE3D1 Nanodiscs 
 
The gene for protein MSPE3D1 was supplied in a PET-28a vector containing a 6xHis 
tag sequence. The protein was expressed and purified according to instructions from 
the Sligar lab, University of Illinois. The plasmid was transformed into E.Coli BL21 
DE3 and cultured in 1L LB medium containing 25 µg Kanamycin at 37C. When the 
OD600 reached 0.6, expression was induced with 1mM IPTG and the temperature 
reduced to 28°C. After 3 hours the cells were harvested by centrifugation at 5000 x g 
for 15 minutes. For extraction and purification, the cells were resuspended in PBS 
with 1% Triton X-100 and lysed by sonication. The lysate was centrifuged at 50,000 x 
g for 30 minutes and the supernatant removed. The supernatant was incubated with 
Ni-NTA beads (0.75 ml per L of culture) for 30 mins before loading into a column. 
The beads were then washed with 40 ml each of: 1. 40 mM Tris/HCl, 0.3 M NaCl, 1% 
Triton, pH 8.0. 2. 40 mM Tris/HCl, 0.3 M NaCl, 50 mM sodium cholate, pH 8.0, 20 
mM imidazole. 3. 40 mM Tris/HCl, 0.3 M NaCl, 50 mM imidazole, pH 8.0. Finally 
the protein was eluted in 40 mM Tris/HCl, 0.3 M NaCl, 0.5 M Imidazole. The protein 
was then dialysed into 10 mM Tris/HCL, 0.1 M NaCl, 0.5 mM EDTA, pH 7.4 and 
stored at 4°C. 
 
The lipids to be constituted into Nanodiscs were dried into a thin layer inside a small 
round bottom flask on a rotary centrifuge, followed by drying in a desiccator 
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overnight. Buffer containing 10 mM Tris/HCL, 0.1 M NaCl, 0.5 mM EDTA, 100 mM 
Sodium Cholate was added to give a final lipid concentration of 50 mM. The lipids 
are solubilised by vortexing the flask, heating it under hot tap water, and sonicating in 
an ultrasonic bath until the solution is clear, and no lipid remains on the walls of the 
flask. MSPE3D1 and the lipid stock are then mixed together in the following rations 
depending on the lipids used: 
Lipid Optimal Ratio for 
MSP1E3D1 
Incubation 
temperature 
DPPC 170:1 37 °C 
DMPC 150:1 25 °C 
POPC / 
POPS 
130:1 4 °C 
Table 24 - Incubation conditions for formation of lipid nanodiscs 
 
The final sodium cholate concentration is adjusted to between 12 – 40 nM if required. 
Nanodiscs are then formed by dialysing the sample against cholate-free buffer over 24 
hours, with a minimum volume of 1000x that of the nanodisc mixture. The crude 
mixture of nanodiscs was finally purified by size exclusion chromatography on a 
HiLoad 16/600 Superdex 200 PG column (GE Healthcare), coupled to an inline 
Dynamic light scattering (DLS) machine (Zetasizer µV, Malvern). The DLS was 
attached to identify nanodiscs of the correct diameter as they came off the column. 
 
6.5.6 Cryo-Electron Microscopy 
 
The Nanodisc and hRSV-M mixture were then prepared for cryo-electron microscopy 
by loading 3-µl aliquots onto freshly glow-discharged c-flat holey carbon grids (CF-
22-4C, Protochips Inc.) held at 4°C and 100% humidity in a Vitrobot vitrification 
robot (FEI). Grids were blotted for 4 s prior to being frozen by plunging into a bath of 
liquid nitrogen-cooled ethane slush. Vitrified specimens were imaged at low 
temperature in a JEOL 2200 FS cryo-microscope equipped with Gatan 626 or Oxford 
CT3500 cryo-stages. Low-dose (10 e/Å2), energy-filtered images (slit width, 20 eV) 
were recorded on a Gatan ultrascan 16-megapixel charge-coupled-device camera at a 
magnification of 100,000×, corresponding to a sample frequency of 1.03 Å/pixel. 
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6.5.7 DLS 
 
Samples for DLS were placed into 10 µl volume, 1 cm pathlength disposable cuvettes 
and placed into a Zetasizer µV DLS machine (Malvern Instruments, Worcestershire, 
UK). The IR laser was at 830 nm wavelength, and the scattering detector at 90° to the 
sample. Measurements were performed in triplicate and averaged. Analysis of 
collected data was done using a protein routine in the Zetasizer software. 
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7 Appendix 
Solubility and Stability Screen HT Formulation for DSF 
Hampton Research - 
Copyright 2012     
        
Rea
gen
t 
W
ell 
[Addi
tive 
1] 
[Addi
tive 
1] Additive 1 
[Additiv
e 2] 
[Additiv
e 2] Additive 2 
# #   units     units   
01 
A
01 100 % v/v Water    
02 
A
02 75 
% 
w/v Trichloroacetic acid    
03 
A
03 250 mM L-Arginine    
04 
A
04 250 mM L-Arginine 250 mM L-Glutamic acid 
05 
A
05 500 mM Glycine    
06 
A
06 500 mM L-Proline    
07 
A
07 120 mM L-Histidine    
08 
A
08 500 mM β-Alanine    
09 
A
09 500 mM L-Serine    
10 
A
10 500 mM 
L-Arginine ethyl ester 
dihydrochloride    
11 
A
11 500 mM 
L-Argininamide 
dihydrochloride    
12 
A
12 500 mM 
6-Aminohexanoic 
acid    
13 
B
01 500 mM Gly-gly    
14 
B
02 200 mM Gly-gly-gly    
15 
B
03 5 
% 
w/v Tryptone    
16 
B
04 2,500 mM 
Betaine 
monohydrate    
17 
B
05 750 mM 
D-(+)-Trehalose 
dihydrate    
18 
B
06 2,000 mM Xylitol    
19 
B
07 2,000 mM D-Sorbitol    
20 
B
08 2,000 mM Sucrose    
21 
B
09 500 mM Hydroxyectoine    
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22 
B
10 2,500 mM 
Trimethylamine N-
oxide dihydrate    
23 
B
11 2,000 mM 
Methyl-α-D-
glucopyranoside    
24 
B
12 10 % v/v Triethylene glycol    
25 
C
01 500 mM 
Spermine 
tetrahydrochloride    
26 
C
02 500 mM Spermidine    
27 
C
03 500 mM 5-Aminovaleric acid    
28 
C
04 500 mM Glutaric acid    
29 
C
05 80 mM Adipic acid    
30 
C
06 500 mM 
Ethylenediamine 
dihydrochloride    
31 
C
07 500 mM 
Guanidine 
hydrochloride    
32 
C
08 500 mM Urea    
33 
C
09 500 mM N-Methylurea    
34 
C
10 200 mM N-Ethylurea    
35 
C
11 30 
% 
w/v N-Methylformamide    
36 
C
12 3 
% 
w/v Hypotaurine    
37 
D
01 100 mM TCEP hydrochloride    
38 
D
02 10 mM 
GSH (L-Glutathione 
reduced) 10 mM 
GSSG (L-Glutathione 
oxidized) 
39 
D
03 5 
% 
w/v 
Benzamidine 
hydrochloride    
40 
D
04 100 mM 
Ethylenediaminetetr
aacetic acid 
disodium salt 
dihydrate    
41 
D
05 100 mM 
Magnesium chloride 
hexahydrate 100 mM 
Calcium chloride 
dihydrate 
42 
D
06 100 mM 
Cadmium chloride 
hydrate 100 mM 
Cobalt(II) chloride 
hexahydrate 
43 
D
07 1,000 mM 
Non Detergent 
Sulfobetaine 195 
(NDSB-195)    
44 
D
08 1,000 mM 
Non Detergent 
Sulfobetaine 201 
(NDSB-201)    
45 
D
09 1,000 mM 
Non Detergent 
Sulfobetaine 211 
(NDSB-211)    
46 
D
10 1,000 mM 
Non Detergent 
Sulfobetaine 221 
(NDSB-221)    
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47 
D
11 1,000 mM 
Non Detergent 
Sulfobetaine 256 
(NDSB-256)    
48 
D
12 500 mM Taurine    
49 
E0
1 500 mM Acetamide    
50 
E0
2 500 mM Oxalic acid dihydrate    
51 
E0
3 500 mM 
Sodium malonate pH 
7.0    
52 
E0
4 500 mM Succinic acid pH 7.0    
53 
E0
5 5 % v/v Tacsimate pH 7.0    
54 
E0
6 25 
% 
w/v 
Tetraethylammoniu
m bromide    
55 
E0
7 25 
% 
w/v Cholin acetate    
56 
E0
8 25 
% 
w/v 
1-Ethyl-3-
methylimidazolium 
acetate    
57 
E0
9 25 
% 
w/v 
1-Butyl-3-
methylimidazolium 
chloride    
58 
E1
0 25 
% 
w/v 
Ethylammonium 
nitrate    
59 
E1
1 500 mM Ammonium sulfate    
60 
E1
2 500 mM Ammonium chloride    
61 
F0
1 500 mM 
Magnesium sulfate 
hydrate    
62 
F0
2 500 mM 
Potassium 
thiocyanate    
63 
F0
3 250 mM 
Gadolinium(III) 
chloride hexahydrate    
64 
F0
4 250 mM Cesium chloride    
65 
F0
5 250 mM 
4-Aminobutyric acid 
(GABA)    
66 
F0
6 500 mM Lithium nitrate    
67 
F0
7 500 mM DL-Malic acid pH 7.0    
68 
F0
8 500 mM 
Lithium citrate 
tribasic tetrahydrate    
69 
F0
9 250 mM Ammonium acetate    
70 
F1
0 250 mM 
Sodium 
benzenesulfonate    
71 
F1
1 250 mM 
Sodium p-
toluenesulfonate    
72 
F1
2 1,000 mM Sodium chloride    
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73 
G
01 1,000 mM Potassium chloride    
74 
G
02 700 mM 
Sodium phosphate 
monobasic 
monohydrate 1,300 mM 
Potassium phosphate 
dibasic 
75 
G
03 1,000 mM 
Sodium sulfate 
decahydrate    
76 
G
04 1,000 mM Lithium chloride    
77 
G
05 1,000 mM Sodium bromide    
78 
G
06 40 % v/v Glycerol 400 mM Lithium chloride 
79 
G
07 50 % v/v Glycerol    
80 
G
08 10 % v/v Ethylene glycol    
81 
G
09 10 % v/v 
Polyethylene glycol 
200    
82 
G
10 5 % v/v 
Polyethylene glycol 
monomethyl ether 
550    
83 
G
11 5 
% 
w/v 
Polyethylene glycol 
monomethyl ether 
750    
84 
G
12 50 % v/v  Formamide    
85 
H
01 50 % v/v 
Polypropylene glycol 
P 400    
86 
H
02 25 % v/v 
Pentaerythritol 
ethoxylate (15/4 
EO/OH)    
87 
H
03 10 
% 
w/v 1,2-Propanediol    
88 
H
04 3 
% 
w/v 
Polyethylene glycol 
monomethyl ether 
1,900    
89 
H
05 3 
% 
w/v 
Polyethylene glycol 
3,350    
90 
H
06 3 
% 
w/v 
Polyethylene glycol 
8,000    
91 
H
07 2 
% 
w/v 
Polyvinylpyrrolidone 
K15    
92 
H
08 100 mM 
6-O-α-D-Maltosyl-β-
cyclodextrin    
93 
H
09 10 mM 
(2-Hydroxypropyl)-β-
cyclodextrin    
94 
H
10 80 mM α-Cyclodextrin    
95 
H
11 10 mM β-Cyclodextrin    
96 
H
12 50 mM 
Methyl-β-
cyclodextrin    
 
